

Supporting Online Material for

**A Unified Approach to Couple Aromatic Heteronucleophiles to
Azines and Pharmaceuticals**

Ryan G. Anderson, Brianna M. Jett, and Andrew McNally*

Department of Chemistry, Colorado State University,
Fort Collins, Colorado 80523, United States.

*andy.mcnally@colostate.edu

Table of Contents

1. General Information	<i>S2</i>
2. Challenging Substrates & Limitations	<i>S3</i>
3. Preparation of Heterocyclic Phosphonium Salt and Aromatic Heteronucleophile Precursors	<i>S5</i>
4. Preparation of Heterocyclic Phosphonium Salts	<i>S9</i>
5. Preparation of Derivatized Azaarenes	<i>S28</i>
6. References	<i>S79</i>
7. ¹H, ¹³C, ¹⁹F and ³¹P Spectra	<i>S80</i>

1. General Information

Proton nuclear magnetic resonance (^1H NMR) spectra were recorded at ambient temperature on either a Bruker Ultrashield-400 (400 MHz) spectrometer, a Varian 400 MR (400 MHz) spectrometer or an Agilent Inova 400 (400 MHz) spectrometer. Chemical shifts (δ) are reported in ppm and quoted to the nearest 0.01 ppm relative to the residual protons in CDCl_3 (7.26 ppm), C_6D_6 (7.16 ppm), $(\text{CD}_3)_2\text{SO}$ (2.50 ppm), CD_3OD (3.31 ppm) or CD_3CN (1.94 ppm) and coupling constants (J) are quoted in Hertz (Hz). Data are reported as follows: Chemical shift (number of protons, multiplicity, coupling constants). Coupling constants were quoted to the nearest 0.1 Hz and multiplicity reported according to the following convention: s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, sext = sextet, sp = septet, m = multiplet, br = broad. Where coincident coupling constants have been observed, the apparent (app) multiplicity of the proton resonance has been reported. Carbon nuclear magnetic resonance (^{13}C NMR) spectra were recorded at ambient temperature on either a Bruker Ultrashield-400 (400 MHz) spectrometer, a Varian 400 MR spectrometer (100 MHz) or an Agilent Inova 400 (100 MHz) spectrometer. Chemical shift (δ) was measured in ppm and quoted to the nearest 0.1 ppm relative to the residual solvent peaks in CDCl_3 (77.0 ppm) or $(\text{CD}_3)_2\text{SO}$ (39.5 ppm). DEPT135, NOE experiments and 2-dimensional experiments (COSY, HMBC and HSQC) were used to support assignments where appropriate.

Low-resolution mass spectra (LRMS) were measured on an Agilent 6310 Quadrupole Mass Spectrometer. Infrared (IR) spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer as either solids or neat films, either through direct application or deposited in CHCl_3 , with absorptions reported in wavenumbers (cm^{-1}).

Analytical thin layer chromatography (TLC) was performed using pre-coated Merck glass backed silica gel plates (Silicagel 60 F254). Flash column chromatography was undertaken on Fluka or Material Harvest silica gel (230–400 mesh) under a positive pressure of air.

Visualization was achieved using ultraviolet light (254 nm) and chemical staining with basic potassium permanganate solution as appropriate.

Tetrahydrofuran (THF), toluene, hexane, diethyl ether and dichloromethane were dried and distilled using standard methods.¹ Ethyl acetate, Dimethoxyethane (DME), 1,4-dioxane, N,N-Dimethylformamide (DMF), chloroform, and acetone were purchased anhydrous from Sigma Aldrich chemical company. All reagents were purchased at the highest commercial quality and used without further purification. Reactions were carried out under an atmosphere of nitrogen unless otherwise stated. All reactions were monitored by TLC, ¹H NMR spectra taken from reaction samples, gas chromatography (GC) and gas chromatography-mass spectrometry (GCMS) using an Agilent 5977A fitted with an Agilent J&W HP-5ms Ultra Inert Column (30 m, 0.25 mm, 0.25 μm film) for MS analysis and an Agilent J&W VF-5ms column (10 m, 0.15 mm, 0.15 μm film) for FID analysis or liquid chromatography mass spectrometry (LCMS) using an Agilent 6310 Quadrupole Mass Spectrometer. Melting points (mp) were recorded using a Büchi B-450 melting point apparatus and are reported uncorrected.


PPh₃ (99%) was purchased from Oakwood Chemical and is most effective when crushed to a powder before use. Tf₂O (99%) was purchased from Oakwood Chemical and used without further purification but was routinely stored in a -20 °C fridge. NEt₃ and DBU were distilled before use. NaH (60% in mineral oil) was purchased from Sigma Aldrich and was typically distributed into vials and stored in a desiccator. KH (36.3% in Paraffin) was purchased from Sigma Aldrich and was kept in a Glovebox. *n*-BuLi (1.6M in Hexanes) was purchased from Sigma Aldrich and routinely stored in a -20 °C fridge. 15-Crown-5 was purchased from Oakwood Chemical Company and distilled before use and stored in a -20 °C fridge. 18-Crown-6 was purchased from Sigma Aldrich and routinely stored in a -20 °C fridge.


2. Challenging Substrates & Limitations

Some nucleophiles and heterocyclic phosphonium salts were unsuccessful for the coupling protocol disclosed in this communication. These cases are stated below along with hypothesized rationales of their unfavorable outcomes.


Nucleophiles:


All these nucleophiles were subjected to deprotonation conditions followed by the addition of Triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (1a).


 Primary anilines do not form coupled products and we believe that the mechanism below is operative. An intermediate iminophosphorane is detected by LCMS and gives credibility to the mechanistic proposal.




m/z LRMS (ESI + APCI) found $[M + H]^+$ 354.2, $C_{14}H_9F_3NS^+$ requires 354.1

 - Diphenyl amine showed no desired product formation. We believe that there is an unfavorable steric interaction from the phenyl rings in the P(V) intermediate that disfavors ligand-coupling to form the C–N bond. Indole and carbazole are also unfavorable as coupling partners and again, our hypothesis is that unfavorable steric interactions from the C–H bonds on the aryl groups disfavor ligand-coupling.


 - Only trace product was detected by LCMS for this 1,2,4-triazole when KH, 18-crown-6 & THF were used. All other reaction conditions didn't show any evidence of the desired coupled product. A trend in this coupling process is that nucleophiles that are too electron-deficient can be unsuitable as coupling partners.

 - 3-chlorophenol only produced 8% by of the desired product by crude 1H NMR when ran at 60 °C using NaH, 15-crown-5 and THF. This trend of low yields was consistent among all other mono-halogenated phenols other than iodine (**2c**) and again indicates that nucleophiles that contain electron-withdrawing groups are less effective as coupling partners.




- Both 2- and 3-hydroxypyridine did not form coupled products. As above, the withdrawing effect of the deficient heterocycle renders the intermediate oxyanion unsuitable for ligand coupling. The precise reasons for this effect are not completely clear at this point and are under investigation in our laboratory.


Limitations of Heterocyclic Phosponium Salts:



- Halogens at the 2-position on the pyridine ring were unfavorable as coupling partners. We observed that an S_NAr pathway was competitive with the desired coupling at the 4-position and resulted in mixtures of products in poor yields. 2-Methoxy pyridine phosphonium salts also resulted in low yields of coupled products.




- 3-position substituted salts were poor coupling partners for aniline nucleophiles resulting in little or no desired product. Cyano groups were the only 3-substituent that underwent coupling with aniline (**2ah**, **2av**).



- 2,6-disubstituted pyridines do not undergo phosphonium salt formation. Unfavorable steric interactions disfavor reaction with Tf_2O meaning the required N-Tf pyridinium salt is not properly formed. Yield for 2,6-disubstituted salts are consequently low (<5%).

3. Preparation of Heterocyclic Phosponium Salt and Aromatic Heteronucleophile Precursors


4-(Thiophen-3-yl)-7-(trifluoromethyl)quinoline



An oven dried 100 mL round bottom flask under N_2 was charged with 4-chloro-7-(trifluoromethyl)quinoline (973 mg, 4.20 mmol), thiophen-3-ylboronic acid (699 mg, 5.46 mmol),

Pd(PPh₃)₄ (97 mg, 0.08 mmol), K₂CO₃ (1.74 g, 12.6 mmol), 12 mL of H₂O and 36 mL of 1,4-dioxane. After 12 hours of stirring the reaction mixture under reflux was quenched with H₂O (20 mL), organic layer separated, and aqueous layer extracted with CH₂Cl₂ (3 x 50 mL). The combined organic extracts were dried (MgSO₄), filtered and concentrated *in vacuo*. The crude material was purified by flash chromatography (silica gel: 16% EtOAc in hexanes) to provide the title compound as brown solid (1.147 g, 4.12 mmol, 98% yield). mp 91–93 °C; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3104, 3064, 1584, 1566, 1506, 1459, 1373, 1325, 1290, 1244, 1219, 1207, 1191, 1156, 1059, 902, 884, 853, 833, 815, 794, 784, 767, 740; ¹H NMR (400 MHz, CDCl₃) δ : 9.01 (1H, d, *J* = 4.4 Hz), 8.47 (1H, s), 8.21 (1H, d, *J* = 8.8 Hz), 7.70 (1H, dd, *J* = 1.2, 8.8 Hz), 7.56–7.54 (2H, m), 7.50 (1H, d, *J* = 4.4 Hz), 7.34 (1H, dd, *J* = 1.4, 4.5 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 151.3, 147.8, 143.3, 137.6, 131.1 (q, *J* = 32.6 Hz), 128.6, 128.3, 127.7 (q, *J* = 4.3 Hz), 127.1, 126.8, 125.4, 123.9 (q, *J* = 271.1 Hz), 122.6, 122.2 (q, *J* = 3.1 Hz); ¹⁹F NMR (365 MHz, CDCl₃) δ : -62.76; *m/z* LRMS (ESI + APCI) found [M + H]⁺ 280.1, C₁₄H₉F₃NS⁺ requires 280.0.


3-Phenyl-5-((pyrimidin-2-yloxy)methyl)isoxazole



An oven dried 100 mL round bottom flask was charged with sodium hydride (60% dispersion in mineral oil, 1.5 equiv.). The flask was subjected to three cycles of vacuum/nitrogen backfill before addition of THF (14 mL). The mixture was cooled to 0 °C and a mixture of (3-phenylisoxazol-5-yl)methanol (1.31 g, 7.50 mmol) in THF (7 mL) was added dropwise over 5 minutes, then allowed to stir for 30 mins at 0 °C. A solution of 2-chloropyrimidine (568 mg, 5 mmol) in THF (7 mL) was then added dropwise to the reaction mixture over 5 minutes. The reaction stirred at 0 °C for 5 minutes then was warmed to room temperature and allowed to stir for 14 hours. The mixture was quenched with water (25 mL) and diluted with CH₂Cl₂ (25 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (3 x

25 mL). The combined organic extracts were washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The crude material was purified by flash chromatography (silica gel: 5% EtOAc in CH₂Cl₂) to provide the title compound as a white solid (993 mg, 3.92 mmol, 78% yield). mp 98-105 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3129, 3088, 3052, 2986, 1948, 2249, 2162, 1965, 1815, 1607, 1578, 1567, 1471, 1401, 1375, 1323, 1290, 1044, 688; ¹H NMR (400 MHz, CDCl₃) δ : 8.57 (2H, d, *J* = 4.8 Hz), 7.83-7.76 (2H, m), 7.48-7.42 (3H, m), 7.02 (1H, t, *J* = 4.8 Hz), 6.70 (1H, s), 5.59 (2H, s); ¹³C NMR (100 MHz, CDCl₃) δ : 168.1, 164.3, 162.5, 159.5, 130.0, 128.9, 128.8, 126.8, 115.8, 101.6, 59.9; *m/z* LRMS (ESI + APCI) found [M + H]⁺ 254.2, C₁₄H₁₂N₃O₂⁺ requires 254.1.


(2R,6S)-2,6-Dimethyl-4-(quinolin-4-ylmethyl)morpholine



An oven-dried 200 mL round bottom flask was charged with 4-quinolinecarboxaldehyde (2.36 g, 15.0 mmol), *cis*-2,6,-dimethylmorpholine (2.03 mL, 16.5 mmol), and sodium triacetoxyhydroborate (6.36 g, 30.0 mmol). The flask was subjected to three cycles of vacuum/nitrogen backfill. CH₂Cl₂ (75 mL) was added to the reaction flask along with glacial AcOH (1.73 mL). After 1 hour stirring at room temperature, the reaction was quenched with a saturated aqueous solution of NH₄Cl (30 mL), diluted with CH₂Cl₂, and the organic layer was separated. The aqueous layer was basified with a saturated aqueous solution of NaHCO₃ and extracted with CH₂Cl₂ (2 x 20 mL). The combined organic extracts were dried (MgSO₄), filtered and concentrated *in vacuo*. The crude material was purified by flash chromatography (silica gel: 50% EtOAc in hexanes) to provide the title compound as a yellow oil (2.98 g, 11.6 mmol, 77% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3035, 2971, 2868, 2813, 2774, 980, 815, 662, 645, 591; ¹H NMR

(400 MHz, CDCl₃) δ : 8.84 (1H, d, J = 4.3 Hz), 8.23 (1H, d, J = 8.4 Hz), 8.11 (1H, d, J = 8.4 Hz), 7.70 (1H, m), 7.54 (1H, m), 7.40 (1H, d, J = 4.3 Hz), 3.87 (2H, s), 3.69 (2H, m), 2.72 (2H, d, J = 10.4 Hz), 1.87 (2H, t, J = 10.7 Hz), 1.13 (6H, d, J = 6.3 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 150.0, 148.3, 143.6, 129.9, 129.1, 127.6, 126.3, 124.2, 121.4, 71.7 (2C), 59.6, 19.0; m/z LRMS (ESI+ APCI) found [M+H]⁺ 257.2, C₁₆H₂₀N₂O⁺ requires 257.2.


1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-hydroxyphenyl)urea (3)



An oven dried 200 mL round bottom flask was charged with 4-aminophenol (546 mg, 5.00 mmol). The flask was subjected to three cycles of vacuum/nitrogen backfill before addition of CH₂Cl₂ (25 mL). A 0.2 M solution of 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene in THF (25 mL) was added dropwise to the reaction flask and stirred at room temperature for 16 hrs. The reaction mixture was then filtered and rinsed with CH₂Cl₂ and H₂O. The material was then further purified by flash chromatography (silica gel: 35% EtOAc in Toluene) to provide the title compound as a white solid (1.11 g, 3.36 mmol, 84% yield). mp 185-195 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3293, 3109, 2359, 1896, 1672, 1623, 1557, 1480, 1326, 1261, 1180, 1145, 1124, 1031, 831; ¹H NMR (400 MHz, (CD₃)₂SO) δ : 9.12 (1H, s), 9.03 (1H, s), 8.48 (1H, s), 8.10 (1H, d, J = 1.6 Hz), 7.64-7.56 (2H, m), 7.23 (2H, d, J = 8.6 Hz), 6.70 (2H, d, J = 8.8 Hz); ¹³C NMR (100 MHz, (CD₃)₂SO) δ : 153.9, 152.6, 139.7, 131.9, 130.5, 126.6 (q, J = 30.7 Hz), 122.9 (q, J = 273.4 Hz), 122.8 (q, J = 4.1 Hz), 121.8, 121.0, 116.5 (q, J = 5.8 Hz), 115.2; ¹⁹F NMR (365 MHz, (CD₃)₂SO) δ : -61.46; m/z LRMS (ESI + APCI) found [M + H]⁺ 331.1, C₁₄H₁₁ClF₃N₂O₂⁺ requires 331.0.

4. Preparation of Heterocyclic Phosponium Salts

General Procedure A




An oven dried 8 mL vial (≤ 0.5 mmol scale) or a round bottom flask (> 0.5 mmol scale) equipped with a stir bar was charged with the heterocycle (1.0 equiv) and placed under a nitrogen atmosphere. CH_2Cl_2 (0.1 M) was added, the reaction vessel cooled to $-78\text{ }^\circ\text{C}$ and Tf_2O (1.0 equiv) was added dropwise over 5 minutes. The reaction was stirred for 30 minutes before PPh_3 (1.1 equiv) was added in one portion. The reaction was subjected to three rapid cycles of vacuum/nitrogen backfill and was stirred for a further 30 minutes at $-78\text{ }^\circ\text{C}$. The stated organic base (NEt_3 or DBU , 1.0 equiv) was added dropwise via syringe, the cooling bath was removed, and the reaction was allowed to warm to room temperature while stirring (approximately 15-30 minutes). The reaction mixture was quenched with H_2O (approximately the same volume as CH_2Cl_2) and the mixture was transferred to a separatory funnel. The mixture was diluted CH_2Cl_2 and the resulting organic layer was washed three times with H_2O . The organic layer was dried (MgSO_4), filtered and concentrated *in vacuo* to approximately 2-10 mL (depending on the scale of the reaction). An excess of chilled Et_2O ($0\text{ }^\circ\text{C}$) was added to the concentrated solution that was then placed in a $-20\text{ }^\circ\text{C}$ refrigerator for approximately 1 hour. The resulting suspension was filtered on a frit, the solid washed with chilled Et_2O ($0\text{ }^\circ\text{C}$) and dried *in vacuo* to provide the pure phosphonium salt.

Notes.

- 1) PPh_3 was crushed into a powder prior to use.
- 2) Certain substrates require longer periods for the precipitation step and specific cases are indicated below.

- 3) In a small number of cases, residual CH₂Cl₂ can become trapped in the phosphonium salt products. In these cases, heating the salts under vacuum (50-100 °C) removed the solvent.
- 4) In order to evaluate regioselectivity from the crude reaction mixtures, a duplicate reaction was performed, and aliquots taken after addition of the organic base and warming to room temperature. These aliquots were concentrated *in vacuo* and analyzed by ¹H and ³¹P NMR.

General Procedure B



An oven dried 8 mL vial (≤ 0.5 mmol scale) or a round bottom flask (> 0.5 mmol scale) equipped with a stir bar was charged with the heterocycle (1.0 equiv) and PPh₃ (1.0 equiv) and placed under a nitrogen atmosphere. CH₂Cl₂ (0.1 M) was added, the reaction vessel cooled to -78 °C and Tf₂O (1.0 equiv) was added dropwise over 5 minutes. The reaction was stirred* for 1 hour before DBU (1.0 equiv) was added dropwise via syringe, the cooling bath removed, and the reaction warmed to room temperature while stirring (approximately 15-30 minutes). The reaction mixture was quenched with H₂O (approximately the same volume as CH₂Cl₂) and the mixture was transferred to a separatory funnel. The mixture was diluted CH₂Cl₂ and the resulting organic layer was washed three times with H₂O. The organic layer was dried (MgSO₄), filtered and concentrated *in vacuo* to approximately 2-10 mL (depending on the scale of the reaction). An excess of chilled Et₂O (0 °C) was added to the concentrated solution that was then placed in a -20 °C refrigerator for approximately 1 hour. The resulting suspension was filtered on a frit, the solid washed with chilled Et₂O (0 °C) and dried *in vacuo* to provide the pure phosphonium salt.


Notes.

- 1) PPh₃ was crushed into a powder prior to use.

* The reaction vessel was placed directly on the middle of the stir plate and the mixture stirred at 1400-2000 rpms for the duration of the reaction.


- 2) Certain substrates require longer periods for the precipitation step and specific cases are indicated below.
- 3) In a small number of cases, residual CH₂Cl₂ can become trapped in the phosphonium salt products. In these cases, heating the salts under vacuum (50-100 °C) removed the solvent.
- 4) In order to evaluate regioselectivity from the crude reaction mixtures, a duplicate reaction was performed, and aliquots taken after addition of the organic base and warming to room temperature. These aliquots were concentrated *in vacuo* and analyzed by ¹H and ³¹P NMR

Triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (1a)



Prepared according to our previous report.² ¹H NMR (400 MHz, CDCl₃) δ: 9.01 (1H, app t, *J* = 5.1 Hz), 7.93-7.54 (18H, m), 7.50 (1H, ddd, *J* = 17.8, 5.1, 1.1 Hz), 7.42-7.36 (3H, m); ¹³C NMR (100 MHz, CDCl₃) δ: 159.1 (d, *J* = 9.9 Hz), 151.6 (d, *J* = 10.7 Hz), 136.7 (d, *J* = 1.5 Hz), 136.1 (d, *J* = 3.2 Hz), 134.3 (d, *J* = 9.8 Hz), 130.9 (d, *J* = 13.0 Hz), 130.4, 129.23 (d, *J* = 84.1 Hz), 129.0, 127.0, 125.3 (d, *J* = 7.8 Hz), 123.1, (d, *J* = 8.4 Hz), 120.7 (q, *J* = 321.1 Hz), 115.5 (d, *J* = 89.1 Hz). The spectroscopic data is in agreement with our previous synthesis.²


Triphenyl(3-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate



Prepared according to our previous report.² ¹H NMR (400 MHz, CDCl₃) δ: 8.95 (1H, app t, *J* = 4.7 Hz), 8.74 (1H, d, *J* = 6.8 Hz), 7.85-7.73 (3H, m), 7.73-7.40 (13H, m), 7.11 (1H, t, *J* = 7.6 Hz),


6.91 (2H, app t, $J = 7.6$ Hz), 6.71 (2H, d, $J = 7.5$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 153.6 (d, $J = 8.0$ Hz), 150.0 (d, $J = 10.4$ Hz), 141.7 (d, $J = 7.3$ Hz), 135.4 (d, $J = 3.0$ Hz), 134.4 (d, $J = 4.5$ Hz), 134.2 (d, $J = 10.3$ Hz), 130.6 (d, $J = 13.0$ Hz), 129.2, 128.9, 128.3, 128.2, 126.4 (d, $J = 83.4$ Hz), 120.8 (q, $J = 321.2$ Hz), 116.9 (d, $J = 89.2$ Hz). The spectroscopic data is in agreement with our previous synthesis.²

Triphenyl(5,6,7,8-tetrahydroquinolin-4-yl)phosphonium trifluoromethanesulfonate



Prepared according to our previous report.² ^1H NMR (400 MHz, DMSO-d_6) δ : 8.74 (1H, app t, $J = 5.1$ Hz), 8.07-7.93 (3H, m), 7.92-7.71 (12H, m), 6.94 (1H, dd, $J = 15.3, 5.1$ Hz), 3.12-2.97 (2H, m), 2.21-2.04 (2H, m), 1.84-1.71 (2H, m), 1.60-1.44 (2H, m); ^{13}C NMR (100 MHz, CDCl_3) δ : 160.3 (d, $J = 8.4$ Hz), 148.2 (d, $J = 11.4$ Hz), 135.5 (d, $J = 7.6$ Hz), 135.3 (d, $J = 3.1$ Hz), 134.1 (d, $J = 10.7$ Hz), 130.5 (d, $J = 13.0$ Hz), 126.2 (d, $J = 9.9$ Hz), 125.5 (d, $J = 82.4$ Hz), 120.4 (q, $J = 322.0$ Hz), 116.3 (d, $J = 87.7$ Hz), 32.0 (d, $J = 2.3$ Hz), 29.7 (d, $J = 5.3$ Hz), 21.0, 20.5. The spectroscopic data is in agreement with our previous synthesis.²

(3-Cyano-5-(thiophen-3-yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate




Major
11.4:1 Mixture of Regioisomers

Prepared according to our previous report.³ ^1H NMR (400 MHz, DMSO-d_6) δ : 9.45 (1H, d, $J = 5.0$ Hz), 9.07 (1H, d, $J = 5.5$ Hz), 7.98-7.84 (9H, m), 7.77-7.67 (6H, m), 7.21-7.16 (1H, m), 7.13 (1H,


br s), 6.57 (1H, d, $J = 4.9$ Hz); Major isomer, ^{13}C NMR (100 MHz, DMSO- d_6) δ : 157.0 (d, $J = 6.9$ Hz), 154.7 (d, $J = 5.8$ Hz), 140.2 (d, $J = 5.5$ Hz), 135.3 (d, $J = 3.0$ Hz), 134.5 (d, $J = 10.8$ Hz), 130.4 (d, $J = 13.3$ Hz), 128.5, 128.3 (d, $J = 84.5$ Hz), 128.3, 127.8, 120.7 (q, $J = 322.4$ Hz), 117.0 (d, $J = 88.5$ Hz), 113.9 (d, $J = 6.0$ Hz), 113.2 (d, $J = 4.4$ Hz).

Triphenyl(4-(thiophen-3-yl)-7-(trifluoromethyl)quinolin-2-yl)phosphonium trifluoromethanesulfonate




Prepared according to general procedure B (except the reaction was cooled to -50 °C for the Tf_2O addition, then cooled to -78 °C for the DBU addition) using 4-(thiophen-3-yl)-7-(trifluoromethyl)quinoline (805 mg, 2.88 mmol), PPh_3 (831 mg, 3.17 mmol), Tf_2O (484 μL , 2.88 mmol) and CH_2Cl_2 (29 mL). After the purification procedure the pure phosphonium salt was isolated as an off-white solid (1.68 g, 2.33 mmol, 81% yield). mp 234-237 °C; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3064, 1739, 1575, 1540, 1501, 1484, 1439, 1421, 1378, 1335, 1224, 1167, 1140, 1108, 1065, 1030, 997, 918, 835, 797, 785, 748, 728, 701, 689, 663, 631; ^1H NMR (400 MHz, CDCl_3) δ : 8.52 (1H, s), 8.40 (1H, d, $J = 8.9$ Hz), 7.92–7.87 (4H, m), 7.82–7.75 (14H, m), 7.55 (1H, dd, $J = 3.0, 4.7$ Hz), 7.34 (1H, $J = 4.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 148.6, 148.3, 147.5, 146.5 (d, $J = 10.5$ Hz), 146.4, 135.9 (d, $J = 2.9$ Hz), 135.5 (d, $J = 1.5$ Hz), 134.7 (d, $J = 10.1$ Hz), 133.2 (q, $J = 33.2$ Hz), 130.7 (d, $J = 12.9$ Hz), 128.6 (d, $J = 2.4$ Hz), 128.3, 128.1, 128.0, 127.8, 125.9–125.6 (m), 123.2 (q, $J = 271.7$ Hz), 120.7 (q, $J = 319.6$ Hz), 116.7 (d, $J = 88.0$ Hz); ^{19}F NMR (365 MHz, CDCl_3) δ : $-63.08, -78.20$; ^{31}P NMR (162 MHz, CDCl_3) δ : 15.62; m/z LRMS (ESI + APCI) found $[\text{M-OTf}]^+$ 540.2, $\text{C}_{32}\text{H}_{22}\text{F}_3\text{NPS}^+$ requires 540.1.

Triphenyl(2-methoxypyridin-4-yl)phosphonium trifluoromethanesulfonate



Prepared according to general procedure A using 2-methoxypyridine (52.5 μL , 0.50 mmol), PPh_3 (144 mg, 0.55 mmol), Tf_2O (84 μL , 0.50 mmol), DBU (75 μL , 0.50 mmol) and CH_2Cl_2 (5.0 mL). After the purification procedure, the title compound was isolated as a white solid (174 mg, 0.34 mmol, 67% yield). mp 149-154 $^\circ\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3063, 2956, 2360, 1980, 1583, 1438, 1380, 1264, 1143, 1107, 1031, 722, 635; ^1H NMR (400 MHz, CDCl_3) δ : 8.57 (1H, t, $J = 5.3$ Hz), 7.97-7.87 (3H, m), 7.85-7.74 (6H, m), 7.71-7.59 (6H, m), 7.12 (1H, dd, $J = 11.5$ Hz, 5.0 Hz), 6.84 (1H, d, $J = 15.0$ Hz), 4.01 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 164.5 (d, $J = 15.7$ Hz), 149.8 (d, $J = 10.5$ Hz), 136.1 (d, $J = 2.9$ Hz), 134.2 (d, $J = 10.5$ Hz), 130.9 (d, $J = 13.5$ Hz), 130.5 (d, $J = 85.2$ Hz), 120.7 (q, $J = 321.2$ Hz), 118.8 (d, $J = 8.3$ Hz), 116.2 (d, $J = 10.0$ Hz), 115.6 (d, $J = 89.6$ Hz), 54.3; ^{19}F NMR (365 MHz, CDCl_3) δ : -78.17; ^{31}P NMR (162 MHz, CDCl_3) δ : 22.37; m/z LRMS (ESI + APCI) found $[\text{M-OTf}]^+$ 519.1, $\text{C}_{24}\text{H}_{21}\text{NOP}^+$ requires 519.1.

(5-(4-Methoxyphenyl)pyrimidin-4-yl)triphenylphosphonium trifluoromethanesulfonate




24:1 Mixture of Regioisomers

Prepared according to our previous report.² Major isomer, ^1H NMR (400 MHz, CDCl_3) δ : 9.44 (1H, s), 8.98 (1H, d, $J = 9.0$ Hz), 7.80-7.70 (3H, m), 7.67-7.56 (12H, m), 6.91 (2H, d, $J = 8.7$ Hz), 6.55 (2H, d, $J = 8.7$ Hz), 3.72 (3H, s); Minor isomer, ^1H NMR (400 MHz, CDCl_3) δ : 9.23 (2H, s),


7.80-7.70 (3H, m), 7.70 (2H, d, $J = 8.7$ Hz), 7.67-7.56 (12H, m), 7.09 (2H, d, $J = 8.6$ Hz), 3.88 (3H, s); Major isomer, ^{13}C NMR (100 MHz, CDCl_3) δ : 161.8 (d, $J = 5.3$ Hz), 160.5, 157.0 (d, $J = 16.8$ Hz), 149.7 (d, $J = 114.5$ Hz), 142.7 (d, $J = 19.2$ Hz), 135.2 (d, $J = 3.1$ Hz), 134.7 (d, $J = 10.2$ Hz), 130.6, 130.3 (d, $J = 13.1$ Hz), 123.6, 120.8 (q, $J = 321.3$ Hz), 117.1 (d, $J = 88.6$ Hz), 114.4, 55.4.

(3-Cyanopyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate




Prepared according to our previous report.⁴ ^1H NMR (400 MHz, CDCl_3) δ : 9.21 (1H, dd, $J = 4.2$, 4.1), 9.16 (1H, d, $J = 5.5$ Hz), 7.95–7.91 (3H, m), 7.83–7.71 (13H, m); ^{13}C NMR (100 MHz, CDCl_3) δ : 155.5 (d, $J = 9.2$ Hz), 154.9 (d, $J = 5.5$ Hz), 136.4 (d, $J = 3.1$ Hz), 134.7 (d, $J = 10.7$ Hz), 131.0 (d, $J = 13.3$ Hz), 130.9 (d, $J = 82.7$ Hz), 130.2 (d, $J = 7.4$ Hz), 120.6 (q, $J = 319.6$ Hz), 114.4 (d, $J = 89.5$ Hz), 113.6 (d, $J = 5.1$ Hz), 111.8.

(3-Cyano-5-(3-fluorophenyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate




Prepared according to our previous report.⁵ ^1H NMR (400 MHz, CDCl_3) δ : 9.10 (1H, dd, $J = 4.9$, 1.2 Hz), 8.83 (1H, dd, $J = 5.5$, 1.1 Hz), 7.92-7.44 (15H, m), 7.02-6.92 (1H, m), 6.84-6.73 (2H, m), 6.70 (1H, d, $J = 8.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.6 (d, $J = 247.8$ Hz), 152.8, 147.3, 140.1, 137.6 (d, $J = 7.9$ Hz), 135.6, 130.3 (d, $J = 8.4$ Hz), 129.0, 128.7, 127.9, 125.4 (d, $J = 3.1$ Hz), 116.7 (d, $J = 22.5$ Hz), 116.0 (d, $J = 21.0$ Hz), 115.1.

Triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium trifluoromethanesulfonate




Prepared according to our previous report.² ¹H NMR (400 MHz, CDCl₃) δ: 9.33 (1H, d, *J* = 2.8 Hz), 8.02 (1H, m), 7.92 (3H, m), 7.82–7.69 (13H, m); ¹³C NMR (100 MHz, CDCl₃) δ: 154.2 (d, *J* = 19.9 Hz), 147.0 (d, *J* = 121.0 Hz), 139.9 (qd, *J* = 35.8 Hz, 11.3 Hz), 136.0 (d, *J* = 2.9 Hz), 134.5 (d, *J* = 10.2 Hz), 130.7 (d, *J* = 13.1 Hz), 126.1 (dq, *J* = 25.9, 3.6 Hz), 124.4 (m), 121.5 (qd, *J* = 274.1, 3.0 Hz), 120.7 (q, *J* = 320.5 Hz), 115.9 (d, *J* = 90.0 Hz). The spectroscopic data is in agreement with our reported synthesis.²

(4-Methylquinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate




Prepared according to our previous report.³ ¹H NMR (400 MHz, CDCl₃) δ: 8.22-8.12 (2H, m), 7.94-7.65 (17H, m), 7.53, (1H, d, *J* = 4.6 Hz), 2.81 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ: 148.5 (d, *J* = 10.6 Hz), 148.5 (d, *J* = 22.6 Hz), 144.4 (d, *J* = 117.2 Hz), 135.6 (d, *J* = 3.1 Hz), 134.6 (d, *J* = 10.1 Hz), 131.6, 130.6 (d, *J* = 1.2 Hz), 130.5 (d, *J* = 12.9 Hz), 130.4, 128.8, 125.1 (d, *J* = 26.4 Hz), 124.4 (d, *J* = 1.3 Hz), 120.8 (q, *J* = 321.2 Hz), 117.3 (d, *J* = 88.2 Hz), 19.2 (d, *J* = 1.5 Hz).

(5-Bromo-2-(methylthio)pyrimidin-4-yl)triphenylphosphonium trifluoromethanesulfonate




Prepared according to our previous report.³ ¹H NMR (400 MHz, CDCl₃) δ: 8.82 (1H, d, *J* = 7.9 Hz), 7.97-7.85 (3H, m), 7.83-7.66 (12H, m), 2.15 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ: 173.9 (d, *J* = 17.2 Hz), 162.0 (d, *J* = 4.1 Hz), 151.4 (d, *J* = 118.7 Hz), 136.1 (d, *J* = 3.1 Hz), 134.8 (d, *J* = 10.4 Hz), 130.7 (d, *J* = 13.3 Hz), 120.9 (q, *J* = 321.2 Hz), 120.9 (d, *J* = 17.1 Hz), 115.0 (d, *J* = 89.9 Hz), 14.4.

Triphenyl(quinoxalin-2-yl)phosphonium trifluoromethanesulfonate




Prepared according to our previous report.⁶ ¹H NMR (400 MHz, CDCl₃) δ: 8.99 (1H, s), 8.27-8.22 (2H, m), 8.09-8.01 (2H, m), 7.93-7.90 (3H, m), 7.79-7.72 (12H, m); ¹³C NMR (100 MHz, CDCl₃) δ: 145.9 (d, *J* = 25.4 Hz), 143.4 (d, *J* = 2.8 Hz), 142.7 (d, *J* = 17.3 Hz), 140.8 (d, *J* = 111.6 Hz), 136.2 (d, *J* = 3.1 Hz), 135.0, 134.7 (d, *J* = 10.5 Hz), 133.1, 130.9 (d, *J* = 13.0 Hz), 130.2 (d, *J* = 2.0 Hz), 129.9 (d, *J* = 2.3 Hz), 120.8 (q, *J* = 319.5 Hz), 116.0 (d, *J* = 88.1 Hz).

[2,2'-Bipyridin]-4-yltriphenylphosphonium trifluoromethanesulfonate



Prepared according to our previous report.² ¹H NMR (400 MHz, CDCl₃) δ: 9.06 (1H, app t, *J* = 5.1 Hz), 8.65 (1H, d, *J* = 13.8 Hz), 8.55 (1H, d, *J* = 4.4 Hz), 8.46 (1H, d, *J* = 7.9 Hz), 7.96-7.88 (3H, m), 7.87-7.74 (7H, m), 7.72-7.55 (7H, m), 7.35 (1H, dd, *J* = 7.7, 4.5 Hz); ¹³C NMR (100 MHz, CDCl₃) δ: 157.8 (d, *J* = 9.9 Hz), 153.4 (d, *J* = 2.3 Hz), 151.4 (d, *J* = 10.7 Hz), 149.3, 137.3, 136.2 (d, *J* = 3.1 Hz), 134.4 (d, *J* = 9.9 Hz), 131.0 (d, *J* = 13.0 Hz), 129.3 (d, *J* = 83.9 Hz), 126.9 (d, *J* = 8.4 Hz), 125.1, 123.9 (d, *J* = 9.2 Hz), 121.7, 120.8 (q, *J* = 321.2 Hz), 115.8 (d, *J* = 89.3 Hz).


(4-(((2R,6S)-2,6-Dimethylmorpholino)methyl)quinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate



Prepared according to general procedure B (except the reaction was cooled to -50 °C for the Tf₂O addition, then cooled to -78 °C for the DBU addition) using (2R,6S)-2,6-dimethyl-4-(quinolin-4-ylmethyl)morpholine (558 mg, 2.18 mmol), PPh₃ (629.3 mg, 2.39 mmol), Tf₂O (340 μL, 2.18 mmol), DBU (325 μL, 2.18 mmol) and CH₂Cl₂ (22 mL). After the purification procedure, the title compound was isolated as a white solid (994 mg, 1.49 mmol, 68% yield). mp 188-195 °C; IR ν_{max}/cm⁻¹ (film): 3072, 2972, 2937, 2825, 1576, 1439, 1267, 1144, 1110, 1027, 727, 633; ¹H NMR


(400 MHz, CDCl₃) δ : 8.26 (2H, dd, J = 8.4, 16.5 Hz), 7.96-7.70 (18H, m), 4.02 (2H, s), 3.50-3.38 (2H, m), 2.60 (2H, d, J = 10.7 Hz), 1.92 (2H, t, J = 10.5 Hz), 1.10 (6H, d, J = 6.2 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 149.0 (d, J = 22.2 Hz), 148.2 (d, J = 10.1 Hz), 144.7 (d, J = 117.6 Hz), 135.7 (d, J = 3.0 Hz), 134.7 (d, J = 10.0 Hz), 131.7, 130.9, 130.6, 130.6 (d, J = 12.9 Hz), 127.9 (d, J = 3.1 Hz), 124.0, 123.6 (d, J = 27.4 Hz), 120.9 (q, J = 321.1 Hz), 117.4 (d, J = 88.2 Hz), 71.6, 59.3, 58.1, 18.9 ; ¹⁹F NMR (365 MHz, CDCl₃) δ : -78.09; ³¹P NMR (162 MHz, CDCl₃) δ : 14.47; m/z LRMS (ESI + APCI) found 517.3 [M-OTf]⁺, C₃₄H₃₄N₂OP⁺ requires 517.2.

(5-Cyano-2-isopropylpyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate




Prepared according to general procedure A using 6-isopropylnicotinonitrile (438.6 mg, 3.0 mmol), Tf₂O (500 μ L, 3.0 mmol), PPh₃ (866 mg, 3.3 mmol), DBU (450 μ L, 3.0 mmol) and CH₂Cl₂ (30 mL). After the purification procedure, the title compound was isolated as an off-white solid (1.02 g, 1.83 mmol, 61% yield). mp 59-66 °C; IR ν_{max} /cm⁻¹ (film): 3063, 2970, 2933, 2873, 2228, 1571, 1481, 1439, 1259, 1147, 1106, 1029; ¹H NMR (400 MHz, CDCl₃) δ : 9.10 (1H, d, J = 5.8 Hz), 7.96-7.90 (3H, m), 7.86-7.73 (12H, m), 7.34 (1H, d, J = 15.3 Hz), 3.20 (1H, sp, J = 6.9 Hz), 1.27 (6H, d, J = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 174.5 (d, J = 8.9 Hz), 154.8 (d, J = 6.1 Hz), 136.3 (d, J = 3.0 Hz), 134.6 (d, J = 10.8 Hz), 131.0 (d, J = 82.5 Hz), 131.0 (d, J = 13.4 Hz), 127.6 (d, J = 7.5 Hz), 120.6 (q, J = 321.2 Hz), 114.4 (d, J = 89.8 Hz), 113.9 (d, J = 5.2 Hz), 108.9 (d, J = 3.7 Hz), 36.9, 21.5; ¹⁹F NMR (365 MHz, CDCl₃) δ : -78.22; ³¹P NMR (162 MHz, CDCl₃) δ : 23.07; m/z LRMS (ESI + APCI) found [M-OTf]⁺ 407.2, C₂₇H₂₄N₂P⁺ requires 407.2.

**Triphenyl(2-((pyridin-3-ylmethyl)thio)pyrimidin-4-yl)phosphonium
trifluoromethanesulfonate**



Prepared according to our previous report.⁷ Major isomer, ¹H NMR (400 MHz, CDCl₃) δ: 9.04 (1H, dd, *J* = 7.6, 5.0 Hz), 8.54-8.35 (2H, m), 8.03-7.57 (17H, m), 7.34-7.11 (1H, m), 4.29 (2H, s); Major isomer, ¹³C NMR (100 MHz, CDCl₃) δ: 173.7 (d, *J* = 17.6 Hz), 160.6 (d, *J* = 7.4 Hz), 154.6 (d, *J* = 111.5 Hz), 149.6, 148.6, 136.2, 136.1 (d, *J* = 2.9 Hz), 134.6 (d, *J* = 10.3 Hz), 132.2, 130.7 (d, *J* = 13.1 Hz), 123.4, 123.1 (d, *J* = 20.3 Hz), 120.7 (q, *J* = 321.1 Hz), 114.9 (d, *J* = 88.9 Hz), 32.5.

**Triphenyl(3'-(trifluoromethyl)-[2,2':5',3''-terpyridin]-4''-yl)phosphonium
trifluoromethanesulfonate**




13.4:1:1 Mixture of Regioisomers

Prepared according to our previous report.³ Major Isomer, ¹H NMR (400 MHz, CDCl₃) δ: 9.08 (1H, app t, *J* = 4.7 Hz), 8.79 (1H, d, *J* = 6.8 Hz), 8.70 (1H, d, *J* = 4.7 Hz), 8.27 (1H, d, *J* = 1.7 Hz), 7.87-7.58 (18H, m), 7.55 (1H, d, *J* = 7.8 Hz), 7.39 (1H, dd, *J* = 7.8, 4.7 Hz); Major Isomer, ¹³C NMR (100 MHz, CDCl₃) δ: 156.1, 155.3, 153.1 (d, *J* = 7.3 Hz), 151.3 (d, *J* = 9.9 Hz), 151.0, 150.6,


148.8, 136.4, 136.2-136.1(m), 135.7 (d, $J = 6.5$ Hz), 135.7 (d, $J = 2.8$ Hz), 134.2 (d, $J = 10.3$ Hz), 130.7 (d, $J = 13.0$ Hz), 128.7 (d, $J = 9.0$ Hz), 127.5 (d, $J = 83.1$ Hz), 123.9 (q, $J = 33.8$ Hz), 123.8, 123.4, 122.2 (q, $J = 273.7$ Hz), 120.6 (q, $J = 321.3$ Hz), 116.2 (d, $J = 88.6$ Hz).

(2-(Bis(3-(trifluoromethyl)phenyl)methyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate




Prepared according to our previous report.³ ^1H NMR (400 MHz, CDCl_3) δ : 8.99 (1H, app t, $J = 5.1$ Hz), 7.91-7.80 (3H, m), 7.78-7.66 (6H, m), 7.63-7.37 (15H, m), 7.29 (1H, d, $J = 13.8$ Hz), 5.97 (1H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 164.0 (d, $J = 9.8$ Hz), 151.6 (d, $J = 10.4$ Hz), 141.7, 136.1 (d, $J = 3.1$ Hz), 134.3 (d, $J = 10.5$ Hz), 132.9 (d, $J = 1.1$ Hz), 130.9 (d, $J = 13.1$ Hz), 130.7 (q, $J = 32.2$ Hz), 130.0, 129.6 (d, $J = 83.7$ Hz), 127.0 (d, $J = 8.7$ Hz), 125.7-125.4 (2C, m), 124.0 (q, $J = 3.8$ Hz), 123.8 (q, $J = 272.5$ Hz), 120.8 (q, $J = 321.2$ Hz), 115.4 (d, $J = 89.5$ Hz), 57.8.

Triphenyl(2-((3-phenylisoxazol-5-yl)methoxy)pyrimidin-4-yl)phosphonium trifluoromethanesulfonate



Prepared according to general procedure B (except the reaction was cooled to $-50\text{ }^{\circ}\text{C}$ for the Tf_2O addition, then cooled to $-78\text{ }^{\circ}\text{C}$ for the DBU addition and EtOAc was used instead of CH_2Cl_2) using 3-phenyl-5-((pyrimidin-2-yloxy)methyl)isoxazole (253.3 mg, 3.0 mmol), PPh_3 (865.6 mg, 3.3 mmol), Tf_2O (0.50 mL, 3.0 mmol), DBU (0.45 mL, 3.0 mmol) and EtOAc (15 mL). After the purification procedure, the title compound was isolated as an off-white solid (798.6 mg, 1.20 mmol, 40% yield). mp $49\text{-}55\text{ }^{\circ}\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3500, 3064, 2162, 1980, 1613, 1587, 1547, 1439, 1352, 1259, 1223, 1149, 1109, 1029, 688, 635, 529; ^1H NMR (400 MHz, CDCl_3) δ : 9.10 (1H, t, $J = 6.8$ Hz), 7.90-7.83 (3H, m), 7.82-7.67 (15H, m), 7.49-7.43 (3H, m), 6.69 (1H, s), 5.58 (2H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 166.6, 164.4 (d, $J = 19.5$ Hz), 163.8 (d, $J = 8.4$ Hz), 162.5, 156.0 (d, $J = 112.4$ Hz), 136.1 (d, $J = 3.0$ Hz), 134.7 (d, $J = 10.4$ Hz), 130.7 (d, $J = 13.1$ Hz), 130.2, 128.9, 128.4, 126.8, 122.5 (d, $J = 20.2$ Hz), 120.7 (q, $J = 320.2$ Hz), 115.1 (d, $J = 89.1$ Hz), 102.4, 60.6; ^{19}F NMR (365 MHz, CDCl_3) δ : -78.20; ^{31}P NMR (162 MHz, CDCl_3) δ : 16.36; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 513.2, $\text{C}_{33}\text{H}_{26}\text{N}_2\text{O}_2\text{P}^+$ requires 513.2.


(2-((4-Chlorophenyl)((1-(ethoxycarbonyl)piperidin-4-yl)oxy)methyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate



Prepared according to our previous report.³ ^1H NMR (400 MHz, CDCl_3) δ : 8.90 (1H, t, $J = 5.1$ Hz), 7.94-7.86 (3H, m), 7.82-7.73 (6H, m), 7.71-7.59 (7H, m), 7.49 (1H, ddd, $J = 12.6, 5.0, 1.1$ Hz), 7.34-7.25 (4H, m), 5.71 (1H, s), 4.11 (2H, q, $J = 7.1$ Hz), 3.70-3.60 (1H, m), 3.55-3.42 (2H, m), 3.25-3.12 (2H, m), 1.79-1.56 (2H, m), 1.54-1.37 (2H, m), 1.25 (3H, t, $J = 7.1$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 164.4 (d, $J = 9.6$ Hz), 155.4, 151.1 (d, $J = 10.5$ Hz), 138.7, 136.2 (d, $J = 3.1$ Hz), 134.5 (d, $J = 10.5$ Hz), 134.0, 131.0 (d, $J = 13.1$ Hz), 129.3 (d, $J = 84.1$ Hz), 128.8, 128.5,


125.9 (d, $J = 8.4$ Hz), 123.9 (d, $J = 9.1$ Hz), 120.8 (q, $J = 321.2$ Hz), 115.8 (d, $J = 89.4$ Hz), 79.9, 72.8, 61.3, 40.7 (rot), 40.7, 31.3, 30.4 (rot), 14.7.

(3-((4-(2-Methylquinolin-4-yl)piperazin-1-yl)methyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate



Prepared according to our previous report.⁴ ^1H NMR (400 MHz, CDCl_3) δ : 9.15 (1H, d, $J = 6.8$ Hz), 8.84 (1H, app t, $J = 4.6$ Hz), 7.91-7.70 (17H, m), 7.54 (1H, dd, $J = 7.4, 7.8$ Hz), 7.33 (1H, dd, $J = 7.6, 7.5$ Hz), 7.20 (1H, dd, $J = 5.0, 15.6$ Hz), 6.59 (1H, s), 3.26 (2H, s), 2.81 (4H, s), 2.62 (3H, s), 2.16 (4H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 159.1, 156.4, 153.5 (d, $J = 8.3$ Hz), 150.8 (d, $J = 10.6$ Hz), 148.4, 137.0 (d, $J = 5.7$ Hz), 135.7 (d, $J = 2.9$ Hz), 134.0 (d, $J = 10.2$ Hz), 131.0 (d, $J = 13.0$ Hz), 129.3, 129.1 (d, $J = 9.8$ Hz), 128.5, 126.7 (d, $J = 81.7$ Hz), 124.6, 123.2, 121.3, 120.8 (q, $J = 319.4$ Hz), 117.0 (d, $J = 88.9$ Hz), 109.2, 59.1 (d, $J = 3.3$ Hz), 52.7, 51.2, 25.1.


((6R,10S)-8-Benzyl-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxalin-2-yl)triphenylphosphonium trifluoromethanesulfonate



Prepared according to our previous report.² ^1H NMR (400 MHz, CDCl_3) δ : 9.09 (1H, s), 8.10-7.72 (17H, m), 7.20-7.05 (3H, m), 6.92-6.80 (2H, m), 3.55-3.27 (4H, m), 3.03-2.87 (2H, m),


2.66-2.42 (2H, m), 2.29-2.15 (1H, m), 1.87 (1H, d, $J = 10.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 144.9 (d, $J = 23.5$ Hz), 144.2, 143.5 (d, $J = 16.9$ Hz), 137.5 (br s), 136.0 (d, $J = 2.9$ Hz), 134.6 (d, $J = 10.9$ Hz), 130.7 (d, $J = 13.0$ Hz), 129.2-126.2 (3C, m), 120.7 (br s), 120.7 (q, $J = 321.5$ Hz), 116.4 (d, $J = 88.3$ Hz), 61.3, 57.9-56.1 (2C, m), 43.1-40.4 (3C, m).

(4-((R)-(Benzyloxy)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methyl)quinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate




Prepared according to our previous report.⁶ ^1H NMR (400 MHz, CDCl_3) δ : 8.54 (1H, d, $J = 8.1$ Hz), 8.26 (1H, d, $J = 8.6$ Hz), 7.94 (1H, t, $J = 7.2$ Hz), 7.91-7.60 (17H, m), 7.29-7.02 (3H, m), 7.14-7.02 (2H, m), 5.83-5.45 (2H, m), 5.07-4.89 (2H, m), 4.60 (1H, d, $J = 11.4$ Hz), 4.33 (1H, d, $J = 11.4$ Hz), 3.52-3.06 (3H, m), 2.84-2.62 (2H, m), 2.49-2.33 (1H, br s), 2.06-1.47 (5H, m); ^{13}C NMR (100 MHz, CDCl_3) δ : 149.2 (d, $J = 22.1$ Hz), 148.5, 145.1, 143.9, 139.5, 136.6, 135.7 (d, $J = 3.0$ Hz), 134.5 (d, $J = 10.0$ Hz), 132.0-131.8 (3C, m), 131.2, 130.4 (d, $J = 13.2$ Hz), 128.4, 127.9, 127.2, 126.7 (d, $J = 3.1$ Hz), 126.1, 123.8, 120.6 (q, $J = 320.3$ Hz), 117.0 (d, $J = 87.7$ Hz), 115.6, 71.8, 60.7, 55.6, 43.0, 38.3, 26.9, 25.8.

(5-Chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-4'-yl)triphenylphosphonium trifluoromethanesulfonate




Prepared according to our previous report.⁶ ¹H NMR (400 MHz, CDCl₃) δ: 8.28 (1H, d, *J* = 7.1 Hz), 8.10 (2H, d, *J* = 8.2 Hz), 7.86-7.62 (16H, m), 7.51-7.45 (3H, m), 7.20 (1H, d, *J* = 16.5 Hz), 3.14 (3H, s), 2.54 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ: 160.8 (d, *J* = 11.2 Hz), 152.4 (d, *J* = 7.3 Hz), 147.5 (d, *J* = 2.2 Hz), 146.1, 141.5, 141.0, 138.9, 135.6, 134.8 (d, *J* = 2.9 Hz), 134.1 (d, *J* = 10.0 Hz), 133.3 (d, *J* = 3.6 Hz), 132.1, 130.8 (d, *J* = 10.2 Hz), 130.0 (d, *J* = 13.1 Hz), 129.8, 128.5, 128.2 (d, *J* = 86.2 Hz), 120.8 (q, *J* = 321.1 Hz), 119.3 (d, *J* = 91.8 Hz), 43.9, 24.6. The spectroscopic data is in agreement with our reported synthesis.⁶

(8-Chloro-11-(1-(ethoxycarbonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate




Prepared according to our previous report.² ¹H NMR (400 MHz, CDCl₃) δ: 8.73 (1H, app t, *J* = 5.0 Hz), 7.97-7.87 (3H, m), 7.86-7.74 (6H, m), 7.73-7.60 (6H, m), 7.16-7.01 (3H, m), 6.71 (1H, s), 4.14 (2H, q, *J* = 7.0 Hz), 3.84-3.61 (2H, m), 3.45- 3.20 (3H, m), 2.75 (1H, dt, *J* = 17.4, 4.7 Hz), 2.58 (1H, dt, *J* = 14.9, 4.7 Hz), 2.53-2.30 (3H, m), 2.26-2.09 (1H, m), 1.60-1.43 (1H, m), 1.25 (3H, t, *J* = 7.2 Hz); ¹³C NMR (100 MHz, CDCl₃) δ: 163.6 (d, *J* = 8.3 Hz), 155.4, 149.1 (d, *J* = 11.4 Hz), 139.2, 136.8, 136.7 (d, *J* = 6.8 Hz), 136.0 (d, *J* = 3.1 Hz), 134.2 (d, *J* = 10.7 Hz), 133.9, 133.6, 132.4, 131.6, 131.1 (d, *J* = 13.0 Hz), 129.9, 127.2 (d, *J* = 10.0 Hz), 127.0 (d, *J* = 82.2 Hz), 126.4, 120.8 (q, *J* = 321.3 Hz), 116.4 (d, *J* = 88.5 Hz), 61.4, 44.6, 44.4, 30.7, 30.4, 30.4, 29.4, 14.6. The spectroscopic data is in agreement with our reported synthesis.²

(3-((3S,8R,9S,10R,13S,14S)-3-Acetoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate



Prepared according to our previous report.⁶ ¹H NMR (400 MHz, CDCl₃) δ: 8.99 (1H, d, *J* = 7.2 Hz), 8.72 (1H, app t, *J* = 4.1 Hz), 7.88-7.59 (15H, m), 7.27 (1H, dd, *J* = 15.7, 5.2 Hz), 5.55 (1H, s), 5.28 (1H, d, *J* = 3.4 Hz), 4.58 (1H, m), 2.33-2.18 (2H, m), 1.99 (3H, s), 1.87-1.30 (10H, m), 1.24-1.01 (5H, m), 0.94 (3H, s), 0.79 (1H, td, *J* = 12.1, 3.7 Hz), 0.57 (1H, td, *J* = 11.2, 3.9 Hz), -0.22 (1H, m); ¹³C NMR (100 MHz, CDCl₃) δ: 170.4, 150.6 (d, *J* = 7.5 Hz), 149.0 (d, *J* = 4.2 Hz), 148.7 (d, *J* = 10.8 Hz), 139.9, 139.1, 137.4 (d, *J* = 6.1 Hz), 135.5 (d, *J* = 2.9 Hz), 134.2 (d, *J* = 9.9 Hz), 130.8 (d, *J* = 13.0 Hz), 130.0 (d, *J* = 10.5 Hz), 125.2 (d, *J* = 83.7 Hz), 121.6, 120.7 (q, *J* = 321.2 Hz), 118.0 (d, *J* = 89.6 Hz), 73.5, 55.3, 49.7, 48.7, 37.9, 36.8, 36.4, 33.5, 32.4, 31.0, 29.7, 27.5, 21.3, 20.3, 19.0, 18.6. The spectroscopic data is in agreement with our reported synthesis.⁶


(2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate



Prepared according to our previous report.⁶ ¹H NMR (400 MHz, CDCl₃) δ: 8.55 (1H, app t, *J* = 5.3 Hz), 7.93-7.87 (3H, m), 7.82-7.74 (6H, m), 7.67-7.59 (6H, m), 7.30-7.23 (2H, m), 7.13 (1H,

ddd, $J = 11.7, 5.3, 1.2$ Hz), 7.02 (1H, t, $J = 7.4$ Hz), 6.94-6.77 (7H, m), 5.66 (1H, sext, $J = 5.3$ Hz), 4.18-4.07 (2H, m), 1.48 (3H, d, $J = 6.4$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 163.7 (d, $J = 15.9$ Hz), 158.1, 154.7, 150.3, 149.8 (d, $J = 12.1$ Hz), 136.1 (d, $J = 3.0$ Hz), 134.3 (d, $J = 10.6$ Hz), 130.9 (d, $J = 13.0$ Hz), 130.8 (d, $J = 84.2$ Hz), 129.5, 122.4, 120.8 (q, $J = 321.2$ Hz), 120.6, 119.1 (d, $J = 8.1$ Hz), 117.5, 116.6 (d, $J = 10.0$ Hz), 115.6 (d, $J = 89.4$ Hz), 115.6, 71.5, 70.5, 16.4.


(3-(2-((2-Methyl-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)phenyl)amino)pyrimidin-4-yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate



20:1 Mixture of Regioisomers

Prepared according to our previous report.⁶ Major isomer, ^1H NMR (400 MHz, DMSO-d_6) δ : 10.14 (1H, s), 9.55 (1H, d, $J = 6.7$ Hz), 9.09 (1H, app t, $J = 4.6$ Hz), 8.31 (1H, d, $J = 5.1$ Hz), 8.00-7.55 (18H, m), 7.52-7.20 (5H, m), 7.08 (1H, d, $J = 8.3$ Hz), 6.10 (1H, br), 3.55 (2H, s), 2.70-2.13 (11H, m), 1.74 (3H, s); Major isomer, ^{13}C NMR (100 MHz, DMSO-d_6) δ : 165.2, 159.8, 159.7 (d, $J = 2.0$ Hz), 158.3, 152.7 (d, $J = 11.4$ Hz), 151.8 (d, $J = 6.8$ Hz), 141.1 (br), 137.3, 136.2, 135.8 (d, $J = 3.8$ Hz), 134.7 (d, $J = 2.3$ Hz), 133.9 (d, $J = 10.0$ Hz), 130.8 (d, $J = 10.2$ Hz), 130.0, 129.9 (d, $J = 13.4$ Hz), 128.7, 127.7, 125.6 (d, $J = 86.2$ Hz), 125.5, 120.7 (q, $J = 322.8$ Hz), 119.5 (d, $J = 92.3$ Hz), 117.0, 117.0, 115.6, 110.3, 60.6, 53.2, 50.1, 43.1, 17.0. The spectroscopic data is in agreement with our reported synthesis.⁶


(5-Cyclopropyl-2-(methoxycarbonyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate



Prepared according to general procedure A (except the reaction was cooled to $-50\text{ }^{\circ}\text{C}$ for the PPh_3 addition) using methyl 5-cyclopropylpicolinate (200 mg, 1.12 mmol), Tf_2O (190 μL , 1.12 mmol), PPh_3 (323 mg, 1.23 mmol), DBU (170 μL , 1.12 mmol) and CH_2Cl_2 (11.2 mL). After the purification procedure, the title compound was isolated as a white solid (276 mg, 0.469 mmol, 42% yield). mp: $173\text{-}200\text{ }^{\circ}\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3069, 2953, 1745, 1577, 1439, 1263, 1133, 1030, 721, 635; ^1H NMR (400 MHz, CDCl_3) δ : 8.47 (1H, d, $J = 6.4$ Hz), 7.96-7.88 (3H, m), 7.87-7.78 (6H, m), 7.78-7.68 (7H, m), 3.94 (3H, s), 1.44 (1H, sp, $J = 4.7$ Hz), 1.08-1.00 (2H, m), 0.92-0.84 (2H, m); ^{13}C NMR (100 MHz, CDCl_3) δ : 163.9 (d, $J = 2.4$ Hz), 147.8 (d, $J = 6.3$ Hz), 146.9 (d, $J = 7.6$ Hz), 146.4 (d, $J = 10.7$ Hz), 136.2 (d, $J = 3.0$ Hz), 134.2 (d, $J = 10.6$ Hz), 131.2 (d, $J = 13.2$ Hz), 129.0 (d, $J = 11.1$ Hz), 127.5 (d, $J = 84.2$ Hz), 120.8 (q, $J = 321.1$ Hz), 115.9 (d, $J = 89.0$ Hz), 53.3, 16.4 (d, $J = 6.5$ Hz), 13.9; ^{19}F NMR (365 MHz, CDCl_3) δ : -78.17; ^{31}P NMR (162 MHz, CDCl_3) δ : 22.15; m/z LRMS (ESI + APCI) found $[\text{M-OTf}]^+$ 438.2, $\text{C}_{28}\text{H}_{25}\text{NO}_2\text{P}^+$ requires 438.2.

5. Preparation of Derivatized Azaarenes

General Procedure C




An oven dried 8 mL vial equipped with a septa cap was charged with sodium hydride (60% dispersion in mineral oil, 1.5 equiv) and placed under a nitrogen atmosphere. THF (0.5 M) was added and the suspension was cooled to 0 °C while stirring. The phenol or thiophenol (1.5 equiv) was added dropwise over 5 min and allowed to stir for 30 min at 0 °C. The septa cap was briefly removed and the phosphonium salt (1.0 equiv) was added in one portion. The reaction was subjected to three rapid cycles of vacuum/nitrogen backfill and was warmed to 60 °C and stirred for 2 h. The reaction was quenched with H₂O, the aqueous layer was separated and extracted with CH₂Cl₂ (3x). The combined organic extracts were washed with a saturated aqueous solution of brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography under the stated conditions to provide the heteroaryl ether/thioether.

Notes.

- 1) If the phenol/thiophenol was a solid or viscous liquid, it was added dropwise as a 1.5 M solution to an equivalent volume 1.5 M solution of NaH in THF.
- 2) Certain substrates required longer reaction times. Specific cases are indicated below.
- 3) Certain substrates showed improved yields when ran in DME at 80 °C. Specific cases are indicated below.
- 4) Certain substrates showed improved yields with the addition of 15-crown-5 right before the salt addition. Specific cases are indicated below (Phenol nucleophiles typically require this addition for tolerable yields).

General Procedure D




An oven dried 8 mL vial equipped with a septa cap was charged with sodium hydride (60% dispersion in mineral oil, 1.5 equiv) and placed under a nitrogen atmosphere. THF (0.5 M) was added and the suspension was cooled to 0 °C while stirring. The pyrrole/pyrazole/imidazole (1.5 equiv) was added dropwise over 5 min and allowed to stir for 30 min at 0 °C. The septa cap

was briefly removed and the phosphonium salt (1.0 equiv) was added in one portion. The reaction was subjected to three rapid cycles of vacuum/nitrogen backfill and was warmed to 60 °C and stirred for 1 h. The reaction was quenched with H₂O, the aqueous layer was separated and extracted with CH₂Cl₂ (3x). The combined organic extracts were washed with a saturated aqueous solution of brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography under the stated conditions to provide the coupled azaarene product.

Notes.

- 1) If the pyrrole/pyrazole/imidazole was a solid or viscous liquid, it was added dropwise as a 1.5 M solution to an equivalent volume 1.5 M solution of NaH in THF.
- 2) Certain substrates required longer reaction times. Specific cases are indicated below.
- 3) Certain substrates showed improved yields when ran in DME at 80 °C. Specific cases are indicated below.
- 4) Certain substrates showed improved yields with the addition of 15-crown-5 right before the salt addition. Specific cases are indicated below.
- 5) Certain substrates showed improved yields when KH was used as the base in place of NaH. Specific cases are indicated below.

General Procedure E




An oven dried 8 mL vial equipped with a septa cap was charged with the aniline (1.5 equiv) and placed under a nitrogen atmosphere. THF (0.25 M) was added and the suspension was cooled to -78 °C while stirring. *n*-BuLi (1.5 equiv) was added dropwise over 5 min and allowed to stir for 30 min at -78 °C. The reaction was then allowed to warm to room temp before the septa cap was briefly removed and the phosphonium salt (1.0 equiv) was added in one portion. The reaction was subjected to three rapid cycles of vacuum/nitrogen backfill and stirred for 30 min at room temp. The reaction was quenched with H₂O, the aqueous layer was separated and extracted

with CH₂Cl₂ (3x). The combined organic extracts were washed with a saturated aqueous solution of brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography under the stated conditions to provide the heteroaryl ether/thioether.

Notes.


- 1) Certain substrates required longer reaction times. Specific cases are indicated below.

4-(4-Methoxyphenoxy)-2-phenylpyridine (2a)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.5 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH₂Cl₂ and dry loading (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2a) as a clear oil (107 mg, 0.39 mmol, 77% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3066, 3002, 2947, 2842, 2214, 2042, 1612, 1564, 1499, 1470, 1259, 1208, 1112, 908, 728; ¹H NMR (400 MHz, CDCl₃) δ : 8.51 (1H, d, J = 5.6 Hz), 7.94-7.88 (2H, m), 7.48-7.37 (3H, m), 7.23 (1H, d, J = 2.3 Hz), 7.10-7.04 (2H, m), 6.99-6.93 (2H, m), 6.74 (1H, dd, J = 5.7, 2.4 Hz), 3.85 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ : 166.3, 159.5, 157.1, 151.1, 147.4, 139.2, 129.1, 128.7, 126.9, 122.0, 115.2, 110.2, 108.5, 55.7; m/z LRMS (ESI + APCI) found [M+H]⁺ 278.1, C₁₈H₁₆NO₂⁺ requires 278.1.

4-Phenoxy-2-phenylpyridine (2b)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), phenol (71 mg, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 4% EtOAc & 1% AcOH in hexanes) afforded the *title compound* (2b) as a yellow amorphous solid (87 mg, 0.35 mmol, 70% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3062, 2923, 2851, 2215, 1721, 1579, 1562, 1489, 1470, 1305, 1214, 912, 774, 731, 692; ^1H NMR (400 MHz, CDCl_3) δ : 8.54 (1H, d, $J = 5.6$ Hz), 7.95-7.88 (2H, m), 7.49-7.38 (5H, m), 7.30-7.24 (2H, m), 7.17-7.12 (2H, m), 6.78 (1H, dd, $J = 5.6, 2.3$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.6, 159.7, 154.2, 151.2, 139.1, 130.2, 129.1, 128.7, 126.9, 125.3, 120.7, 110.7, 109.1; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 248.1, $\text{C}_{17}\text{H}_{14}\text{NO}^+$ requires 248.1.


4-(4-Iodophenoxy)-2-phenylpyridine (2c)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-iodophenol (165 mg, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50


mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH₂Cl₂ and dry loading (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2c) as a pink solid (112 mg, 0.30 mmol, 60% yield). mp: 50-57 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3084, 3045, 2925, 2503, 2208, 1879, 1594, 1556, 1477, 1408, 1214, 1023, 844, 694; ¹H NMR (400 MHz, CDCl₃) δ : 8.56 (1H, d, J = 5.6 Hz), 7.95-7.89 (2H, m), 7.77-7.71 (2H, m), 7.50-7.38 (3H, m), 7.27 (1H, d, J = 2.3 Hz), 6.94-6.88 (2H, m), 6.78 (1H, dd, J = 5.6, 2.4 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 165.0, 159.8, 154.3, 151.3, 139.2, 138.9, 129.3, 128.7, 126.9, 122.8, 110.8, 109.2, 88.8; m/z LRMS (ESI + APCI) found [M+H]⁺ 374.0, C₁₇H₁₃INO⁺ requires 374.0.

4-(2-Methoxyphenoxy)-2-phenylpyridine (2d)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 2-methoxyphenol (82 μL , 0.75 mmol), 15-crown-5 (150 μL , 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and DME (1.0 mL). Flash column chromatography by dissolving in CH₂Cl₂ and dry loading (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2d) as a clear oil (79 mg, 0.28 mmol, 57% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3066, 3008, 2927, 2839, 2214, 2043, 1580, 1563, 1498, 1470, 1258, 1208, 1112, 907, 728; ¹H NMR (400 MHz, CDCl₃) δ : 8.50 (1H, d, J = 5.7 Hz), 7.94-7.88 (2H, m), 7.48-7.37 (3H, m), 7.30-7.22 (2H, m), 7.14 (1H, dd, J = 7.9, 1.6 Hz), 7.08-6.99 (2H, m), 6.70 (1H, dd, J = 5.7, 2.4 Hz), 3.81 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ : 165.7, 159.4, 151.7, 150.9, 142.2, 139.3, 129.0, 128.6, 126.9, 126.7, 122.7, 121.3, 113.0, 109.6, 108.2, 55.9; m/z LRMS (ESI + APCI) found [M+H]⁺ 278.2, C₁₈H₁₆NO₂⁺ requires 278.1.

4-(3-Bromo-4-methoxyphenoxy)-2-phenylpyridine (2e)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 3-bromo-4-methoxyphenol (152 mg, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and DME (1.0 mL). Flash column chromatography (basic alumina: 20% EtOAc in hexanes) afforded the *title compound* (2e) as a white solid (92 mg, 0.26 mmol, 52% yield). mp: 88-95 $^{\circ}$ C; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3061, 2979, 2947, 2846, 2497, 2161, 2042, 1848, 1584, 1561, 1486, 1468, 1437, 1409, 1257, 1205, 1043, 875, 776, 694; ^1H NMR (400 MHz, CDCl_3) δ : 8.54 (1H, d, $J = 5.6$ Hz), 7.98-7.88 (2H, m), 7.50-7.36 (4H, m), 7.24 (1H, d, $J = 2.3$ Hz), 7.08 (1H, dd, $J = 8.9, 2.9$ Hz), 6.95 (1H, d, $J = 9.0$ Hz), 6.75 (1H, dd, $J = 5.6, 2.3$ Hz), 3.93 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.8, 159.7, 153.7, 151.2, 147.6, 139.0, 129.2, 128.7, 127.0, 126.2, 120.8, 112.5, 112.2, 110.2, 108.6, 56.7; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 356.1, $\text{C}_{18}\text{H}_{15}\text{BrNO}_2^+$ requires 356.0.


2-Phenyl-4-((5,6,7,8-tetrahydronaphthalen-2-yl)oxy)pyridine (2f)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 5,6,7,8-tetrahydronaphthalen-2-ol (111.2 mg, 0.75 mmol), 15-crown-

5 (150 μL , 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (basic alumina: 2% EtOAc in hexanes) afforded the *title compound* (2f) as a white solid (122 mg, 0.41 mmol, 81% yield). mp: 57-61 $^\circ\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3061, 2925, 2835, 2162, 1579, 1561, 1492, 1469, 1238, 1195, 865, 773, 691; ^1H NMR (400 MHz, CDCl_3) δ : 8.51 (1H, d, $J = 5.7$ Hz), 7.94-7.89 (2H, m), 7.49-7.37 (3H, m), 7.27 (1H, d, $J = 2.3$ Hz), 7.11 (1H, d, $J = 8.2$ Hz), 6.88-6.82 (2H, m), 6.77 (1H, dd, $J = 5.6, 2.4$ Hz), 2.82-2.74 (4H, m), 1.88-1.77 (4H, m); ^{13}C NMR (100 MHz, CDCl_3) δ : 165.9, 159.5, 151.7, 151.1, 139.3 (2C), 134.3, 130.6, 129.1, 128.7, 127.0, 120.9, 117.9, 110.5, 109.0, 29.5, 28.9, 23.1, 22.9; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 302.2, $\text{C}_{21}\text{H}_{20}\text{NO}^+$ requires 302.2.


N-(4-((2-Phenylpyridin-4-yl)oxy)phenyl)acetamide (2g)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), N-(4-hydroxyphenyl)acetamide (151.2 mg, 0.75 mmol), 15-crown-5 (150 μL , 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and DME (1.0 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt_3 : 1% MeOH in DCM) afforded the *title compound* (2g) as a white solid (111 mg, 0.36 mmol, 73% yield). mp: 129-139 $^\circ\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3297, 3206, 3064, 2923, 2852, 1659, 1546, 1501, 1469, 1405, 1302, 1211, 1016, 911, 849, 776, 693; ^1H NMR (400 MHz, CDCl_3) δ : 8.53 (1H, d, $J = 5.6$ Hz), 7.93-7.87 (2H, m), 7.60-7.54 (2H, m), 7.48-7.37 (3H, m), 7.32 (1H, br), 7.25 (1H, d, $J = 2.2$ Hz)


7.13-7.07 (2H, m), 6.77 (1H, dd, $J = 5.7, 2.4$ Hz), 2.20 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 168.3, 165.7, 159.7, 151.2, 150.3, 139.0, 135.3, 129.2, 128.7, 127.0, 121.7, 121.4, 110.5, 108.9, 24.5; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 305.2, $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_2^+$ requires 305.1.

Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-((2-phenylpyridin-4-yl)oxy)phenyl)propanoate (2h)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), methyl (tert-butoxycarbonyl)-L-tyrosinate (222 mg, 0.75 mmol), 15-crown-5 (150 μL , 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel, gradient elution: 30% EtOAc in hexanes to 80% EtOAc in hexanes) afforded the *title compound* (2h) as a white solid (133.1 mg, 0.297 mmol, 59% yield). mp: 29-40 $^\circ\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3435, 3033, 2979, 2932, 2251, 1979, 1742, 1706, 1586, 1504, 1471, 1219, 1163, 908, 728; ^1H NMR (400 MHz, CDCl_3) δ : 8.53 (1H, d, $J = 5.6$ Hz), 7.95-7.90 (2H, m), 7.48-7.37 (3H, m), 7.27 (1H, d, $J = 2.2$ Hz), 7.23-7.18 (2H, m), 7.09-7.04 (2H, m), 6.75 (1H, dd, $J = 5.6, 2.4$ Hz), 5.04 (1H, d, $J = 7.7$ Hz), 4.66-4.56 (1H, m), 3.74 (3H, s), 3.21-3.00 (2H, m), 1.43 (9H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 172.1, 165.4, 159.6, 155.0, 153.2, 151.1, 139.0, 133.3, 131.0, 129.1, 128.6, 126.9, 120.7, 110.6, 109.1, 79.9, 54.4, 52.2, 37.9, 28.2; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 449.3, $\text{C}_{26}\text{H}_{29}\text{N}_2\text{O}_5^+$ requires 449.2.

2-Phenyl-4-(phenylthio)pyridine (2i)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), benzenethiol (77 μ L, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 2.5% EtOAc in hexanes) afforded the *title compound* (2i) as a clear oil (109 mg, 0.42 mmol, 83% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3689, 3064, 3040, 2997, 2921, 2850, 2612, 2459, 2162, 1977, 1814, 1764, 1699, 1567, 1534, 1462, 1379, 757, 693; ^1H NMR (400 MHz, CDCl_3) δ : 8.43 (1H, d, $J = 5.3$ Hz), 7.89-7.84 (2H, m), 7.63-7.56 (2H, m), 7.50-7.36 (7H, m), 6.88 (1H, dd, $J = 5.3, 1.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 157.4, 150.8, 149.4, 139.0, 135.0, 129.9, 129.7, 129.6, 129.1, 128.7, 126.9, 119.4, 117.8; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 264.1, $\text{C}_{17}\text{H}_{14}\text{NS}^+$ requires 264.1.


4-((4-Chlorophenyl)thio)-2-phenylpyridine (2j)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-chlorobenzenethiol (109 mg, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF


(1.0 mL). Flash column chromatography (silica gel: 2.5% EtOAc in Toluene) afforded the *title compound* (2j) as a white crystalline solid (109 mg, 0.37 mmol, 73% yield). mp: 86-90 °C IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3076, 3044, 3012, 2924, 2771, 2464, 1980, 1812, 1585, 1536, 1461, 1378, 1089, 836.8, 797, 690; ^1H NMR (400 MHz, CDCl_3) δ : 8.46 (1H, d, $J = 5.3$ Hz), 7.89-7.85 (2H, m), 7.54-7.49 (2H, m), 7.48-7.38 (6H, m), 6.87 (1H, dd, $J = 5.3, 1.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 157.6, 150.0, 149.5, 138.9, 136.1, 136.0, 130.2, 129.2, 128.8, 128.4, 126.9, 119.4, 117.9; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 298.1, $\text{C}_{17}\text{H}_{13}\text{ClNS}^+$ requires 298.0.

4-((4-Fluorophenyl)thio)-2-phenylpyridine (2k)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-fluorobenzenethiol (80 μL , 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 2.5% EtOAc in Toluene) afforded the *title compound* (2k) as a white solid (110 mg, 0.39 mmol, 78% yield). mp: 75-79 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3090, 3067, 3037, 2923, 2853, 2466, 2040, 1813, 1702, 1585, 1570, 1537, 1489, 1223, 776; ^1H NMR (400 MHz, CDCl_3) δ : 8.44 (1H, d, $J = 5.3$ Hz), 7.92-7.83 (2H, m), 7.65-7.55 (2H, m), 7.48-7.35 (4H, m), 7.22-7.13 (2H, m), 6.83 (1H, dd, $J = 5.3, 1.7$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 163.7 (d, $J = 251$ Hz), 157.5, 150.9, 149.4, 138.9, 137.5 (d, $J = 8.5$ Hz), 129.2, 128.7, 126.9, 124.8 (d, $J = 3.5$ Hz), 118.96, 117.43, 117.23 (d, $J = 21.9$ Hz); ^{19}F NMR (365 MHz, CDCl_3) δ : -110.25; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 282.1, $\text{C}_{17}\text{H}_{13}\text{FNS}^+$ requires 282.1.

2-Phenyl-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thio)pyridine (2l)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenethiol (177 mg, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH₂Cl₂ and dry loading (silica gel: 8% EtOAc in hexanes) afforded the *title compound* (2l) as a yellow oil (119.4 mg, 0.307 mmol, 61% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 2979, 2928, 2247, 2216, 1715, 1569, 1358, 1142, 907, 729; ¹H NMR (400 MHz, CDCl₃) δ : 8.44 (1H, d, $J = 5.3$ Hz), 7.90-7.85 (4H, m), 7.60-7.53 (2H, m), 7.50-7.36 (4H, m), 6.90 (1H, dd, $J = 5.3, 1.7$ Hz), 1.37 (12H, s); ¹³C NMR (100 MHz, CDCl₃) δ : 157.6, 150.1, 149.4, 139.0, 136.0, 133.6, 133.5, 129.1, 128.7, 127.0, 119.9, 118.4, 84.2, 24.9; m/z LRMS (ESI + APCI) found $[M+H]^+$ 390.2, C₂₃H₂₅BNO₂S⁺ requires 390.2.

4-((2-Methoxyphenyl)thio)-2-phenylpyridine (2m)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 2-methoxybenzenethiol (91 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 10% EtOAc in hexanes) afforded the *title compound* (2m) as a clear oil (115 mg, 0.39 mmol, 79% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3062, 2936, 2835, 2167, 1567, 1476, 1462, 1274, 1247, 1022, 753; ^1H NMR (400 MHz, CDCl_3) δ : 8.41 (1H, d, $J = 5.3$ Hz), 7.89-7.84 (2H, m), 7.60-7.54 (1H, m), 7.52-7.36 (5H, m), 7.08-7.00 (2H, m), 6.83 (1H, dd, $J = 5.3, 1.8$ Hz), 3.84 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 159.9, 157.2, 150.1, 149.1, 139.2, 137.2, 131.9, 129.0, 128.7, 126.9, 121.6, 119.1, 117.6, 117.0, 111.7, 56.0; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 294.2, $\text{C}_{18}\text{H}_{16}\text{NOS}^+$ requires 294.1.


4-((2-Bromophenyl)thio)-2-phenylpyridine (2n)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 2-bromobenzenethiol (90 μ L, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel, gradient elution: 10% EtOAc in hexanes to 20% EtOAc in hexanes) afforded the *title compound* (2n) as a brown oil (144 mg, 0.42 mmol, 84% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3056, 2925, 2456, 2162, 1979, 1567, 1536, 1444, 1379, 752, 693; ^1H NMR (400 MHz, CDCl_3) δ : 8.49 (1H, d, $J = 5.3$ Hz), 7.91-7.86 (2H, m), 7.77 (1H, dd, $J = 7.8, 1.2$ Hz), 7.64 (1H, dd, $J = 7.8, 1.7$ Hz), 7.50-7.35 (5H, m), 7.35-7.29 (1H, m), 6.88 (1H, dd, $J = 5.3, 1.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3)


δ : 157.7, 149.6, 148.4, 138.9, 136.5, 134.1, 131.7, 131.0, 129.6, 129.2, 128.7, 128.6, 127.0, 119.9, 118.5; m/z LRMS (ESI + APCI) found $[M+H]^+$ 342.1, $C_{17}H_{13}BrNS^+$ requires 342.0.

4-((3-Methoxyphenyl)thio)-2-phenylpyridine (2o)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 3-methoxybenzenethiol (93 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 10% EtOAc in hexanes) afforded the *title compound* (2o) as a yellow oil (118 mg, 0.40 mmol, 80% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3001, 2933, 2834, 1566, 1479, 1231, 772, 690; ^1H NMR (400 MHz, CDCl_3) δ : 8.44 (1H, d, $J = 5.3$ Hz), 7.90-7.85 (2H, m), 7.47-7.34 (5H, m), 7.17 (1H, d, $J = 7.6$ Hz), 7.13-7.10 (1H, m), 7.00 (1H, dd, $J = 8.3, 2.6$ Hz), 6.90 (1H, dd, $J = 5.3, 1.7$ Hz), 3.83 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 160.5, 157.5, 150.6, 149.4, 139.0, 130.8, 130.7, 129.1, 128.7, 127.1, 126.9, 119.8, 119.5, 118.0, 115.7, 55.5; m/z LRMS (ESI + APCI) found $[M+H]^+$ 294.1, $C_{18}H_{16}NOS^+$ requires 294.1.

2-Phenyl-4-((3-(trifluoromethoxy)phenyl)thio)pyridine (2p)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 3-(trifluoromethoxy)benzenethiol (146 mg, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.5 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 15% EtOAc in hexanes) afforded the *title compound* (2p) as a clear oil (81.8 mg, 0.235 mmol, 47% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 2925, 2853, 2218, 1568, 1251, 1219, 1205, 1165, 907, 730, 692; ^1H NMR (400 MHz, CDCl_3) δ : 8.49 (1H, dd, $J = 5.3, 0.5$ Hz), 7.90-7.85 (2H, m), 7.52-7.38 (7H, m), 7.34-7.28 (1H, m), 6.93 (1H, dd, $J = 5.3, 1.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 157.8, 149.8, 149.7, 149.0, 138.8, 132.6, 132.5, 131.0, 129.3, 128.8, 126.9, 126.6, 121.8, 120.4 (q, $J = 258.2$ Hz), 119.9, 118.5; ^{19}F NMR (365 MHz, CDCl_3) δ : -57.88; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 348.1, $\text{C}_{18}\text{H}_{13}\text{F}_3\text{NOS}^+$ requires 348.1.


4-((2,6-Dimethylphenyl)thio)-2-phenylpyridine (2q)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 2,6-dimethylbenzenethiol (100 μ L, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 2% EtOAc in toluene) afforded the *title compound* (2q) as a clear oil (108 mg, 0.37 mmol, 74% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3054, 2958, 2922, 2459, 2161, 1948, 1727, 1567, 1535, 1460, 1375, 1103, 770, 693; ^1H NMR (400 MHz, CDCl_3) δ : 8.35 (1H, d, $J = 5.3$ Hz), 7.84-7.79 (2H, m), 7.44-7.32 (3H, m), 7.30-7.17 (4H, m), 6.63 (1H, dd, $J = 5.3, 1.8$ Hz), 2.41 (6H, s); ^{13}C NMR (100 MHz,


CDCl₃) δ : 157.3, 150.3, 149.3, 144.1, 139.1, 130.2, 129.0, 128.8, 128.7, 127.6, 126.9, 118.0, 116.6, 21.7; m/z LRMS (ESI + APCI) found $[M+H]^+$ 292.2, C₁₉H₁₈NS⁺ requires 292.1.

2-Phenyl-4-(thiophen-2-ylthio)pyridine (2r)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), thiophene-2-thiol (70 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 2.5% EtOAc in toluene) afforded the *title compound* (2r) as a tan oil (93 mg, 0.35 mmol, 69% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3062, 3036, 2993, 2923, 2360, 2162, 1952, 1567, 1379, 1072, 771, 691; ¹H NMR (400 MHz, CDCl₃) δ : 8.46 (1H, d, J = 5.3 Hz), 7.90-7.85 (2H, m), 7.63 (1H, dd, J = 5.3, 1.2 Hz), 7.48-7.37 (5H, m), 7.19 (1H, dd, J = 5.3, 3.5 Hz), 6.89 (1H, dd, J = 5.3, 1.8 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 157.5, 151.5, 149.4, 139.0, 137.9, 132.9, 129.1, 128.7, 128.5, 127.0, 126.5, 118.2, 116.7; m/z LRMS (ESI + APCI) found $[M+H]^+$ 270.1, C₁₅H₁₂NS₂⁺ requires 270.0.

2-Phenyl-4-(phenylselanyl)pyridine (2s)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), benzeneselenol (80 μ L, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 5% EtOAc in hexanes) afforded the *title compound* (2s) as a white solid (141 mg, 0.45 mmol, 91% yield). mp: 43-47 $^\circ\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3064, 3033, 2923, 2452, 2163, 1961, 1891, 1753, 1562, 1534, 1438, 1379, 1019, 825, 774, 738, 698, 679; ^1H NMR (400 MHz, CDCl_3) δ : 8.41 (1H, d, J = 5.2 Hz), 7.90-7.84 (2H, m), 7.71-7.65 (2H, m), 7.58 (1H, d, J = 1.1 Hz), 7.50-7.36 (6H, m), 7.04 (1H, dd, J = 5.3, 1.6 Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 157.5, 149.4, 146.2, 138.9, 136.1, 129.9, 129.3, 129.1, 128.7, 126.9, 126.5, 122.4, 120.9; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 312.2, $\text{C}_{17}\text{H}_{14}\text{NSe}^+$ requires 312.0.


N-Methyl-N,2-diphenylpyridin-4-amine (2u)



Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 470 μ L, 0.75 mmol), *N*-methylaniline (81 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (2.0 mL). Flash column chromatography (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2u) as a tan powder (117 mg, 0.45 mmol, 90% yield). mp: 77-82 $^\circ\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3061, 3045, 3038, 2917, 2852, 2818, 2592, 2501, 2161, 2050, 1953, 1842, 1603, 1597, 1536, 1480, 1445, 1360, 1235, 1135, 983, 825, 760, 693; ^1H NMR (400 MHz, CDCl_3) δ : 8.32 (1H, d, J = 5.8 Hz), 7.88-7.83 (2H, m), 7.52-7.33 (5H, m), 7.31-7.24 (3H, m), 6.99 (1H, d, J = 2.4 Hz), 6.54 (1H, dd, J = 8.4, 3.4 Hz), 3.39 (3H, s); ^{13}C NMR (100 MHz, CDCl_3)


δ : 158.0, 154.6, 149.8, 146.4, 140.4, 130.0, 128.5, 128.5, 127.0, 126.6, 126.3, 107.2, 105.4, 39.6;
 m/z LRMS (ESI + APCI) found $[M+H]^+$ 261.1, $C_{18}H_{17}N_2^+$ requires 261.1.

N-(3-Ethoxyphenyl)-N-methyl-2-phenylpyridin-4-amine (2v)




Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 234 μ L, 0.38 mmol), 3-ethoxy-N-methylaniline (57 mg, 0.38 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (141 mg, 0.25 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 60% EtOAc in hexanes) afforded the *title compound* (2v) as an orange oil (63 mg, 0.20 mmol, 81% yield). IR ν_{max}/cm^{-1} (film): 2978, 2928, 2162, 1574, 1543, 1478, 1446, 1245, 1203, 1046, 984, 773, 695; 1H NMR (400 MHz, $CDCl_3$) δ : 8.32 (1H, d, $J = 5.8$ Hz), 7.90-7.84 (2H, m), 7.46-7.30 (4H, m), 7.01 (1H, d, $J = 2.4$ Hz), 6.86-6.77 (3H, m), 6.56 (1H, dd, $J = 5.9, 2.5$ Hz), 4.04 (2H, q, $J = 6.9$ Hz), 3.37 (3H, s), 1.42 (3H, t, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ : 160.3, 158.0, 154.5, 149.8, 147.5, 140.4, 130.6, 128.5, 128.5, 127.0, 118.6, 112.8, 112.4, 107.4, 105.6, 63.6, 39.5, 14.8; m/z LRMS (ESI + APCI) found $[M+H]^+$ 305.2, $C_{20}H_{21}N_2O^+$ requires 305.2.

N-Benzyl-N,2-diphenylpyridin-4-amine (2w)



Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 234 μL , 0.38 mmol), *N*-benzylaniline (65 μL , 0.38 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (141 mg, 0.25 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2w) as an orange amorphous solid (52 mg, 0.15 mmol, 62% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3062, 2961, 2930, 2860, 2253, 1715, 1588, 1496, 1385, 1271, 1120, 904, 725, 649; ^1H NMR (400 MHz, CDCl_3) δ : 8.28 (1H, d, $J = 5.9$ Hz), 7.79-7.74 (2H, m), 7.46-7.31 (11H, m), 7.30-7.26 (2H, m), 7.01 (1H, d, $J = 2.4$ Hz), 6.55 (1H, dd, $J = 5.9, 2.5$ Hz), 5.03 (2H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 158.0, 154.1, 149.9, 145.7, 140.3, 137.5, 130.0, 128.8, 128.5, 128.5, 127.3, 126.9, 126.8, 126.5, 126.4, 107.8, 106.0, 56.0; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 337.2, $\text{C}_{24}\text{H}_{21}\text{N}_2^+$ requires 337.2.


1-(2-Phenylpyridin-4-yl)indoline (2x)



Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 0.47 mL, 0.75 mmol), indoline (84.1 μL , 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (282.5 mg, 0.5 mmol) and THF (2.0 mL). Flash column chromatography (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2x) as a brown oil (92.3 mg, 0.339 mmol, 68% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 2978, 2928, 2162, 1574, 1543, 1478, 1446, 1245, 1203, 1046, 984, 773, 695; ^1H NMR (400 MHz, CDCl_3) δ : 8.51 (1H, d, $J = 5.8$ Hz), 7.99-7.94 (2H, m), 7.51-7.45 (3H, m), 7.45-7.37 (2H, m), 7.26-7.16 (2H, m), 7.02 (1H, dd, $J = 5.8, 2.3$ Hz), 6.94-6.88 (1H, m), 4.07 (2H, t, $J = 8.3$ Hz), 3.21 (2H, t, $J = 8.3$ Hz); ^{13}C NMR (100 MHz, CDCl_3)


δ : 158.5, 150.3, 150.2, 144.6, 140.1, 132.2, 128.8, 128.6, 127.2, 127.0, 125.5, 121.0, 110.6, 108.9, 107.2, 51.2, 27.9; m/z LRMS (ESI + APCI) found $[M+H]^+$ 273.1, $C_{19}H_{17}N_2^+$ requires 273.1.

6-Bromo-1-(2-phenylpyridin-4-yl)indoline (2y)



Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 234 μ L, 0.375 mmol), 6-bromoindoline (74 mg, 0.38 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (141 mg, 0.25 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 30% EtOAc in hexanes) afforded the *title compound* (2y) as a white solid (36 mg, 0.10 mmol, 41% yield). mp: 75-80°C; IR ν_{max}/cm^{-1} (film): 3298, 3035, 2956, 2162, 1608, 1574, 1478, 1431, 1270, 988, 769.5, 691.4; 1H NMR (400 MHz, $CDCl_3$) δ : 8.54 (1H, d, $J = 5.8$ Hz), 7.99-7.94 (2H, m), 7.52-7.38 (5H, m), 7.10-7.06 (1H, m), 7.05-6.99 (2H, m), 4.09 (2H, t, $J = 8.4$ Hz), 3.15 (2H, t, $J = 8.4$ Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ : 158.8, 150.4, 149.8, 146.1, 139.8, 131.2, 129.0, 128.7, 127.0, 126.4, 123.6, 120.8, 113.5, 109.2, 107.5, 51.7, 27.5; m/z LRMS (ESI + APCI) found $[M+H]^+$ 351.1, $C_{19}H_{16}BrN_2^+$ requires 351.0.


2-Phenyl-4-(1H-pyrrol-1-yl)pyridine (2z)



Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), pyrrole (52 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-


yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH₂Cl₂ and dry loading (silica gel: 10% EtOAc in hexanes) afforded the *title compound* (2z) as a clear oil (81 mg, 0.37 mmol, 74% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3063, 2925, 2852, 2360, 2340, 2246, 2218, 1718, 1594, 1494, 1351, 1256, 1066, 1176, 905, 723; ¹H NMR (400 MHz, CDCl₃) δ : 8.66 (1H, d, J = 5.2 Hz), 8.00 (2H, d, J = 7.3 Hz), 7.69 (1H, d, J = 1.6 Hz), 7.53-7.41(3H, m), 7.29-7.20 (3H, m), 6.42 (2H, t, J = 1.9 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 159.4, 151.1, 147.3, 139.0, 129.4, 128.8, 127.0, 118.4, 112.2, 112.1, 110.5; m/z LRMS (ESI + APCI) found $[M+H]^+$ 221.1, C₁₅H₁₃N₂⁺ requires 221.1.

4-(1H-Imidazol-1-yl)-2-phenylpyridine (2ab)




Prepared according to general procedure D using potassium hydride (36.3% dispersion in mineral oil, 41 mg, 0.38 mmol), 18-crown-6 (99 mg, 0.38 mmol) was added at the start with potassium hydride, 1H-imidazole (26 mg, 0.38 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (141 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt₃, gradient elution: 60% EtOAc in hexanes to 80% EtOAc in hexanes) afforded the *title compound* (2ab) as a clear oil (28 mg, 0.13 mmol, 51% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3123, 3062, 2924, 2851, 2222, 1979, 1595, 1568, 1496, 1240, 1054, 905, 725, 693; ¹H NMR (400 MHz, CDCl₃) δ : 8.78 (1H, d, J = 5.4 Hz); 8.08 (1H, s), 8.05-8.00 (2H, m), 7.73 (1H, d, J = 1.9 Hz), 7.55-7.44 (4H, m), 7.31-7.26 (2H, m); ¹³C NMR (100 MHz, CDCl₃) δ : 160.0, 151.5, 144.5, 138.3, 135.0, 131.6, 129.8, 129.0, 127.0, 117.0, 113.1, 111.4; m/z LRMS (ESI + APCI) found $[M+H]^+$ 222.1, C₁₄H₁₂N₃⁺ requires 222.1.

2-Phenyl-4-(1H-pyrazol-1-yl)pyridine (2ac)



Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 1H-pyrazole (51 mg, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 15% EtOAc in hexanes) afforded the *title compound* (2ac) as a clear oil (80 mg, 0.36 mmol, 72% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3032, 1591, 1568, 1521, 1482, 1442, 1395, 1381, 1041, 774, 693; ^1H NMR (400 MHz, CDCl_3) δ : 8.72 (1H, d, $J = 5.4$ Hz); 8.20-8.00 (4H, m), 7.80 (1H, d, $J = 1.4$ Hz), 7.59-7.40 (4H, m), 6.58-6.53 (1H, dd, $J = 2.4, 1.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 159.4, 151.0, 146.8, 142.4, 138.8, 129.4, 128.8, 127.1, 126.7, 110.9, 109.5, 109.0; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 222.1, $\text{C}_{14}\text{H}_{12}\text{N}_3^+$ requires 222.1.


4-(4-Bromo-1H-pyrazol-1-yl)-2-phenylpyridine (2ad)



Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-bromo-1H-pyrazole (110 mg, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry


loading (silica gel: 10% EtOAc in hexanes) afforded the *title compound* (2ad) as a white solid (97 mg, 0.32 mmol, 64% yield). mp: 140-143 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3142, 3116, 3029, 2921, 1928, 1694, 1593, 1569, 1478, 1447, 1414, 1406, 1339, 1251, 1148, 954, 777, 703; ^1H NMR (400 MHz, CDCl_3) δ : 8.74 (1H, d, $J = 5.4$ Hz); 8.12 (1H, s), 8.10-8.02 (3H, m), 7.76 (1H, s), 7.56-7.43 (4H, m); ^{13}C NMR (100 MHz, CDCl_3) δ : 159.6, 151.1, 146.2, 142.9, 138.6, 129.6, 128.9, 127.0, 126.8, 110.5, 109.1, 97.4; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 300.1, $\text{C}_{14}\text{H}_{11}\text{BrN}_3^+$ requires 300.0.

4-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-phenylpyridine (2ae)




Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 3,5-dimethyl-1H-pyrazole (72 mg, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 30% EtOAc in hexanes) afforded the *title compound* (2ae) as a clear oil (47 mg, 0.19 mmol, 37% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 2925, 2225, 1710, 1593, 1573, 905, 727; ^1H NMR (400 MHz, CDCl_3) δ : 8.73 (1H, d, $J = 5.4$ Hz), 8.06-8.01 (2H, m), 7.92 (1H, d, $J = 1.7$ Hz), 7.51-7.40 (3H, m), 7.38 (1H, dd, $J = 5.4, 2.0$ Hz), 6.08 (1H, m), 2.50 (3H, s), 2.32 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 159.0, 150.6, 150.6, 147.5, 139.9, 138.9, 129.3, 128.8, 127.0, 115.4, 114.1, 109.3, 13.6, 13.3; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 250.2, $\text{C}_{16}\text{H}_{16}\text{N}_3^+$ requires 250.1.

2-Phenyl-4-(4-phenyl-1H-imidazol-1-yl)pyridine (2af)



Prepared according to general procedure D using potassium hydride (36.3% dispersion in mineral oil, 83 mg, 0.75 mmol), 4-phenylimidazole (108 mg, 0.75 mmol), 18-Crown-6 (198 mg, 0.75 mmol), triphenyl(2-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.5 mmol) and THF (1.0 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt_3 ; 40% EtOAc in hexanes) afforded the *title compound* (2af) as a yellow oil (38 mg, 0.13 mmol, 25% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3058, 2924, 2360, 2341, 2217, 1592, 1568, 1493, 1445, 1238, 1056, 726, 692, 906; ^1H NMR (400 MHz, CDCl_3) δ : 8.78 (1H, d, $J = 5.4$ Hz), 8.11 (1H, s), 8.04 (2H, d, $J = 6.9$ Hz), 7.86 (2H, d, $J = 7.3$ Hz), 7.76 (1H, d, $J = 1.6$ Hz), 7.71 (1H, s), 7.56-7.39 (5H, m), 7.35-7.28 (2H, m); ^{13}C NMR (100 MHz, CDCl_3) δ : 160.0, 151.5, 144.3 (2C), 138.3, 135.1, 133.0, 129.8, 128.9, 128.7, 127.6, 127.0, 125.1, 112.8, 112.1, 111.1; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 298.2, $\text{C}_{20}\text{H}_{16}\text{N}_3^+$ requires 298.1.


4-(4-Methoxyphenoxy)nicotinonitrile (2ag)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 μL , 0.75


mmol), (3-cyanopyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (257 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 50% EtOAc in hexanes) afforded the *title compound* (2ag) as a colorless amorphous solid (90.9 mg, 0.402 mmol, 80% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3062, 2973, 2936, 2839, 2232, 1585, 1567, 1502, 1481, 1277, 1242, 1195, 1179, 1027, 889, 838; ^1H NMR (400 MHz, CDCl_3) δ : 8.77 (1H, s), 8.51 (1H, d, $J = 5.9$ Hz), 7.95-7.10-7.03 (2H, m), 7.00-6.95 (2H, m), 6.64 (1H, d, $J = 5.9$ Hz), 3.84 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 166.7, 158.0, 154.6, 154.4, 145.9, 122.0, 115.4, 114.0, 109.5, 100.5, 55.7; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 227.1, $\text{C}_{13}\text{H}_{11}\text{N}_2\text{O}_2^+$ requires 227.1.

4-(Methyl(phenyl)amino)nicotinonitrile (2ah)




Prepared according to general procedure E using *n*-butyl lithium (1.6 M in hexanes, 470 μL , 0.75 mmol), *N*-methylaniline (81 μL , 0.75 mmol), (3-cyanopyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (257 mg, 0.50 mmol) and THF (2.0 mL). Flash column chromatography (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2ah) as an orange amorphous solid (86 mg, 0.41 mmol, 82% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3018, 2920, 2855, 2208, 1600, 1582, 1495, 1405, 1203, 1051, 809, 698; ^1H NMR (400 MHz, CDCl_3) δ : 8.47 (1H, s), 8.31 (1H, d, $J = 6.2$ Hz), 7.50-7.42 (2H, m), 7.42-7.33 (1H, m), 7.25-7.20 (2H, m), 6.65 (1H, d, $J = 6.2$ Hz), 3.52 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 156.3, 155.0, 152.1, 145.9, 130.3, 127.8, 126.6, 116.8, 110.4, 95.9, 41.8; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 210.1, $\text{C}_{13}\text{H}_{12}\text{N}_3^+$ requires 210.1.

3-Phenyl-4-(phenylthio)pyridine (2ai)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), benzenethiol (77 μ L, 0.75 mmol), triphenyl(3-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 10% EtOAc in toluene) afforded the *title compound* (2ai) as a clear oil (101.2 mg, 0.384 mmol, 77% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3066, 3035, 2997, 2923, 2950, 2612, 1980, 1815, 1763, 1699, 1567, 1462, 1379, 757, 693; ^1H NMR (400 MHz, CDCl_3) δ : 8.37 (1H, s), 8.25 (1H, d, $J=5.4$ Hz), 7.54-7.38 (10H, m), 6.68 (1H, d, $J=5.4$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 149.3, 149.2, 148.3, 136.7, 135.6, 134.8, 130.0, 129.9, 129.7, 129.4, 128.5, 128.4, 120.0; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 264.1, $\text{C}_{17}\text{H}_{14}\text{NS}^+$ requires 264.1.

N-Methyl-N,3-diphenylpyridin-4-amine (2aj)




Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 0.468 mL, 0.75 mmol), N-methylaniline (81.2 μ L, 0.75 mmol), triphenyl(3-phenylpyridin-4-yl)phosphonium trifluoromethanesulfonate (282.6 mg, 0.5 mmol) and THF (2.0 mL).

2-Methoxy-4-(phenylthio)pyridine (2ak)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), benzenethiol (77 μ L, 0.75 mmol), triphenyl(2-methoxypyridin-4-yl)phosphonium trifluoromethanesulfonate (260 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 5% EtOAc in hexanes) followed by filtration through a plug of silica eluting with 100% DCM afforded the *title compound* (2ak) as a clear oil (49 mg, 0.22 mmol, 45% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3060, 2981, 2947, 2857, 2226, 1588, 1542, 1473, 1385, 1035, 905, 728; ^1H NMR (400 MHz, CDCl_3) δ : 7.94 (1H, d, J = 5.5 Hz), 7.57-7.51 (2H, m), 7.46-7.40 (3H, m), 6.60 (1H, dd, J = 5.5, 1.6 Hz) 6.33 (1H, d, J = 1.4 Hz), 3.87 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 164.5, 152.3, 146.4, 135.2, 129.8, 129.6, 129.5, 114.8, 107.2, 53.4; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 218.1, $\text{C}_{12}\text{H}_{12}\text{NOS}^+$ requires 218.1.


N-Methyl-N-phenyl-[2,2'-bipyridin]-4-amine (2al)



Prepared according to general procedure E using *n*-butyl lithium (1.6 M in hexanes, 0.47 mL, 0.75 mmol), *N*-methylaniline (81 μ L, 0.75 mmol), [2,2'-bipyridin]-4-yltriphenylphosphoniumtrifluoromethanesulfonate (283 mg, 0.50 mmol) and THF (2.0 mL). Flash column chromatography (silica gel: 20% EtOAc, 2.5% NEt_3 in hexanes) afforded the *title*


compound (2al) as a tan solid (107 mg, 0.41 mmol, 82% yield). mp: 107-110 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3061, 3002, 2907, 2821, 2538, 2162, 1979, 1604, 1578, 1567, 1542, 1490, 1468, 1456, 1370, 953, 786, 774, 702; ^1H NMR (400 MHz, CDCl_3) δ : 8.60 (1H, d, $J=4.1$ Hz), 8.32 (1H, d, $J=8.0$ Hz), 8.22 (1H, d, $J=5.8$ Hz), 7.80-7.70 (2H, m), 7.45-7.35 (2H, m), 7.25-7.15 (4H, m), 6.52 (1H, dd, $J=5.8, 2.6$ Hz), 3.41 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 156.8, 156.7, 154.8, 149.2, 148.9, 146.5, 136.7, 129.9, 126.6, 126.2, 123.4, 121.2, 108.9, 105.3, 39.7; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 262.1, $\text{C}_{17}\text{H}_{16}\text{N}_3^+$ requires 262.1.

4-(1H-Pyrrol-1-yl)-2,2'-bipyridine (2am)




Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 mmol), 1H-pyrrole (26 μL , 0.38 mmol), [2,2'-bipyridin]-4-yltriphenylphosphonium trifluoromethanesulfonate (142 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (basic alumina: 5% EtOAc in hexanes) afforded the *title compound* (2am) as a tan amorphous solid (36 mg, 0.16 mmol, 64% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3060, 2922, 2851, 2222, 1723, 1598, 1584, 1563, 1496, 1350, 1062, 907, 723, 691; ^1H NMR (400 MHz, CDCl_3) δ : 8.72-8.69 (1H, m), 8.66 (1H, d, $J=5.4$ Hz), 8.50 (1H, d, $J=2.2$ Hz), 8.47-8.43 (1H, m), 7.85 (1H, td, $J=7.8, 1.7$ Hz), 7.39-7.30 (4H, m), 6.42 (2H, t, $J=2.2$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 158.0, 155.5, 150.6, 149.2, 147.4, 137.0, 124.1, 121.3, 118.5, 113.2, 112.1, 110.5; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 222.1, $\text{C}_{14}\text{H}_{12}\text{N}_3^+$ requires 222.1.

2-(4-Methoxyphenoxy)-4-(trifluoromethyl)pyridine (2an)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 mmol), 4-methoxyphenol (47 mg, 0.38 mmol), 15-crown-5 (75 μ L, 0.38 mmol), triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium trifluoromethanesulfonate (139 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 10% EtOAc in hexanes) afforded the *title compound* (2an) as a white solid (54 mg, 0.20 mmol, 80% yield). mp: 76–79 $^\circ\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3073, 3028, 2979, 2921, 2849, 2050, 1758, 1615, 1569, 1503, 1402, 1330, 1294, 1225, 1171, 1137, 1075, 836; ^1H NMR (400 MHz, CDCl_3) δ : 8.32 (1H, d, $J = 5.2$ Hz), 7.16 (1H, dd, $J = 5.2, 0.8$ Hz), 7.11 (1H, t, $J = 1.4$ Hz), 7.10–7.05 (2H, m), 6.97–6.92 (2H, m), 3.83 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 164.7, 157.0, 149.0, 146.6, 141.6 (q, $J = 34.1$ Hz), 122.5 (q, $J = 273.1$ Hz), 122.4, 114.9, 113.7 (q, $J = 3.3$ Hz), 107.6 (q, $J = 4.0$ Hz), 55.6; ^{19}F NMR (365 MHz, CDCl_3) δ : –64.92; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 270.1, $\text{C}_{13}\text{H}_{11}\text{F}_3\text{NO}_2^+$ requires 270.1.


2-(1H-Pyrrol-1-yl)-4-(trifluoromethyl)pyridine (2ao)



Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 1H-pyrrole (52 μ L, 0.75 mmol), triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium trifluoromethanesulfonate (279 mg, 0.50 mmol), and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 2% EtOAc in hexanes) afforded the *title compound* (2ao) as a white solid (70 mg, 0.33 mmol, 66% yield).


mp: 73–77 °C; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3160, 3119, 3048, 2922, 1724, 1615, 1575, 1492, 1437, 1352, 1330, 1300, 1276, 1172, 1128, 1059, 935, 839, 735, 675; ^1H NMR (400 MHz, CDCl_3) δ : 8.59 (1H, d, $J = 5.1$ Hz), 7.55 (2H, t, $J = 2.3$ Hz), 7.48 (1H, s), 7.30 (1H, dd, $J = 0.7, 5.1$ Hz), 6.39 (2H, t, $J = 2.3$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 152.0, 150.0, 140.8 (q, $J = 34.2$ Hz), 122.5 (q, $J = 273.9$ Hz), 118.2, 115.5 (q, $J = 3.4$ Hz), 112.3, 107.1 (q, $J = 3.8$ Hz); ^{19}F NMR (365 MHz, CDCl_3) δ : -64.98 ; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 213.1, $\text{C}_{10}\text{H}_8\text{F}_3\text{N}_2^+$ requires 213.1.

2-(1H-Pyrazol-1-yl)-4-(trifluoromethyl)pyridine (2ap)




Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 1H-pyrazole (51 mg, 0.75 mmol), triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium trifluoromethanesulfonate (279 mg, 0.50 mmol), and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 3% EtOAc in hexanes) afforded the *title compound* (2ap), as a volatile clear oil (31 mg, 0.14 mmol, 29% iso. yield, 76% ^1H NMR yield). Note that the product evaporates during solvent evaporation. IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 2926, 2253, 1577, 1463, 1398, 1345, 1318, 1179, 1149, 1040, 903, 726, 649; ^1H NMR (400 MHz, CDCl_3) δ : 8.60–8.55 (2H, m); 8.25 (1H, s), 7.78 (1H, d, $J = 1.0$ Hz), 7.39 (1H, d, $J = 4.4$ Hz), 6.50 (1H, t, $J = 2.5$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 152.3, 149.3, 142.8, 141.0 (q, $J = 34.2$ Hz), 127.3, 122.5 (q, $J = 273.3$ Hz), 116.8 (q, $J = 3.4$ Hz), 108.8 (q, $J = 4.0$ Hz), 108.5; ^{19}F NMR (365 MHz, CDCl_3) δ : -64.96 ; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 214.1, $\text{C}_9\text{H}_7\text{F}_3\text{N}_3^+$ requires 214.1.

2-(1H-Imidazol-1-yl)-4-(trifluoromethyl)pyridine (2aq)



Prepared according to general procedure D using potassium hydride (36.3% dispersion in paraffin, 83 mg, 0.75 mmol), 1H-imidazole (51 mg, 0.75 mmol), triphenyl(4-(trifluoromethyl)pyridin-2-yl)phosphonium trifluoromethanesulfonate (279 mg, 0.50 mmol), and THF (1.0 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt₃: 40% EtOAc in hexanes) afforded the *title compound* (2aq) as a white solid (78 mg, 0.37 mmol, 73% yield). mp: 61–66 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3119, 3053, 2916, 2848, 2225, 1980, 1673, 1615, 1577, 1481, 1438, 1326, 1176, 1141, 1051, 906, 841, 652; ¹H NMR (400 MHz, CDCl₃) δ : 8.68 (1H, d, $J = 5.1$ Hz), 8.42 (1H, s), 7.68 (1H, t, $J = 1.4$ Hz), 7.54 (1H, s), 7.47 (1H, dd, $J = 0.6, 5.1$ Hz), 7.25 (1H, t, $J = 1.1$ Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 150.5, 149.9, 141.4 (q, $J = 34.3$ Hz), 135.1, 131.4, 122.3 (q, $J = 275.2$ Hz), 117.5 (q, $J = 3.4$ Hz), 116.0, 108.1 (q, $J = 3.8$ Hz); ¹⁹F NMR (365 MHz, CDCl₃) δ : -64.90 ; m/z LRMS (ESI + APCI) found $[M+H]^+$ 214.1, C₉H₇F₃N₃⁺ requires 214.1.


5-(3-Fluorophenyl)-4-(4-methoxyphenoxy)nicotinonitrile (2ar)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), (3-cyano-5-(3-fluorophenyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (304 mg, 0.50 mmol) and THF (1.0 mL). Flash column


chromatography by dissolving in CH₂Cl₂ and dry loading (silica gel: 25% EtOAc in hexanes) afforded the *title compound* (2ar) as a yellow solid (117 mg, 0.37 mmol, 73% yield). mp: 93-97 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3048, 3011, 2954, 2919, 2847, 2235, 1967, 1871, 1583, 1501, 1446, 1432, 1241, 1183, 1031, 878, 794, 696; ¹H NMR (400 MHz, CDCl₃) δ : 8.79 (1H, s), 8.75 (1H, s), 7.40-7.33 (1H, m), 7.24-7.20 (1H, m), 7.19-7.15 (1H, m), 7.10-7.04 (1H, m), 6.84-6.76 (4H, m), 3.76 (3H, m); ¹³C NMR (100 MHz, CDCl₃) δ : 162.6 (d, $J = 246.2$ Hz), 161.8, 156.7, 155.2, 154.7, 149.6, 134.4 (d, $J = 8.1$ Hz), 130.3 (d, $J = 8.4$ Hz), 129.5, 124.9 (d, $J = 3.1$ Hz), 119.0, 116.3 (d, $J = 22.7$ Hz), 115.8 (d, $J = 21.0$ Hz), 114.8, 113.3, 103.5, 55.6; ¹⁹F NMR (365 MHz, CDCl₃) δ : -112.18; m/z LRMS (ESI + APCI) found $[M+H]^+$ 321.2, C₁₉H₁₄FN₂O₂⁺ requires 321.1.

4-(Phenylthio)-5-(thiophen-3-yl)nicotinonitrile (2as)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), benzenethiol (77 μ L, 0.75 mmol), (3-cyano-5-(thiophen-3-yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (298 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2as) as white solid (121 mg, 0.31 mmol, 63% yield). mp: 129-133 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3734, 3111, 3054, 2924, 2498, 2232, 1968, 1867, 1725, 1543, 1438, 1077, 842, 787, 736, 656; ¹H NMR (400 MHz, CDCl₃) δ : 8.74 (1H, s), 8.67 (1H, s), 7.39-7.34 (1H, m), 7.34-7.29 (1H, m), 7.26-7.18 (4H, m), 7.18-7.12 (2H, m); ¹³C NMR (100 MHz, CDCl₃) δ : 153.1, 152.9, 148.0, 135.5, 135.4, 132.3, 131.7, 129.4, 128.4, 128.3, 126.1, 125.7, 115.1, 114.1; m/z LRMS (ESI + APCI) found $[M+H]^+$ 295.1, C₁₆H₁₁N₂S₂⁺ requires 295.0.

5-(3-Fluorophenyl)-4-(1H-pyrrol-1-yl)nicotinonitrile (2at)



Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 mmol), 1H-pyrrole (26 μ L, 0.38 mmol), (3-cyano-5-(3-fluorophenyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (152 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 10% EtOAc in hexanes) afforded the *title compound* (2at) as a brown oil (17 mg, 0.063 mmol, 25% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3019, 2927, 2236, 1613, 1587, 1496, 1485, 1324, 1215, 1063, 907, 729, 696, 668; ^1H NMR (400 MHz, CDCl_3) δ : 8.95 (1H, s); 8.84 (1H, s), 7.37-7.30 (1H, m), 7.09 (1H, td, J = 8.4, 2.6 Hz), 6.85 (1H, d, J = 7.7 Hz), 6.75 (1H, dt, J = 9.3, 1.8 Hz), 6.64 (2H, t, J = 2.1 Hz), 6.30 (2H, t, J = 2.1 Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.9 (d, J = 248.0 Hz), 155.1, 153.8, 147.2, 135.4 (d, J = 8.1 Hz), 132.3, 130.7 (d, J = 8.4 Hz), 124.0 (d, J = 3.1 Hz), 121.5, 116.1 (d, J = 21.0 Hz), 115.3 (d, J = 22.9 Hz), 114.6, 112.0, 107.3; ^{19}F NMR (365 MHz, CDCl_3) δ : -111.30; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 264.1, $\text{C}_{16}\text{H}_{11}\text{FN}_3^+$ requires 264.1.


4-(Phenylthio)-5,6,7,8-tetrahydroquinoline (2au)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), benzenethiol (76.5 μ L, 0.75 mmol), triphenyl(5,6,7,8-tetrahydroquinolin-4-yl)phosphonium trifluoromethanesulfonate (272mg, 0.50 mmol) and DME (1.0 mL). Flash column chromatography (silica gel: 30% EtOAc in toluene) afforded the


title compound (2au) as a white solid (93 mg, 0.39 mmol, 77% yield). mp: 93-98 °C, IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3034, 2861, 2658, 2535, 2184, 1981, 1880, 1724, 1555, 1433, 1402, 1064, 815, 755, 704, 688; ^1H NMR (400 MHz, CDCl_3) δ : 8.05 (1H, d, $J = 5.3$ Hz), 7.55-7.42 (5H, m), 6.41 (1H, d, $J = 5.3$ Hz), 2.91 (2H, t, $J = 8.0$ Hz), 2.73 (2H, t, $J = 8.0$ Hz), 1.94-1.84 (4H, m); ^{13}C NMR (100 MHz, CDCl_3) δ : 156.6, 149.1, 146.1, 135.4, 130.0, 129.9, 129.4, 128.6, 117.7, 32.9, 26.1, 22.8, 22.6; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 242.1, $\text{C}_{15}\text{H}_{16}\text{NS}^+$ requires 242.1.

6-Isopropyl-4-(methyl(phenyl)amino)nicotinonitrile (2av)




Prepared according to general procedure E using *n*-butyl lithium (1.6 M in hexanes, 468 μL , 0.75 mmol), *N*-methylaniline (81 μL , 0.75 mmol), (5-cyano-2-isopropylpyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (278 mg, 0.50 mmol) and THF (2.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2av) as an off-white powder (87 mg, 0.35 mmol, 69% yield). mp: 108-114 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3060, 3007, 2963, 2921, 2868, 2214, 1863, 1752, 1581, 1534, 1492, 1410, 1310, 1051, 877, 698; ^1H NMR (400 MHz, CDCl_3) δ : 8.43 (1H, s), 7.48-7.42 (2H, m), 7.37-7.31 (1H, m), 7.24-7.19 (2H, m), 6.54 (1H, s), 3.49 (3H, s), 2.93 (1H, sp, $J = 6.8$ Hz), 1.26 (6H, d, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 171.1, 155.8, 155.6, 146.2, 130.1, 127.3, 126.4, 117.1, 107.2, 94.2, 41.7, 36.7, 22.1; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 252.2, $\text{C}_{16}\text{H}_{18}\text{N}_3^+$ requires 252.1.

2-(4-Methoxyphenoxy)-4-methylquinoline (2aw)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 μ L, 0.75 mmol), (4-methylquinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate (277 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (basic alumina: 5% EtOAc in hexanes) afforded the *title compound* (2aw) as a white solid (90 mg, 0.34 mmol, 68% yield). mp: 96-100 $^\circ\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3067, 2952, 2920, 2835, 2163, 1615, 1575, 1503, 1463, 1442, 1384, 1336, 1201, 1177, 1022, 828, 756; ^1H NMR (400 MHz, CDCl_3) δ : 7.90 (1H, dd, $J = 8.3, 1.2$ Hz), 7.79 (1H, dd, $J = 8.4, 0.7$ Hz), 7.62-7.57 (1H, m), 7.45-7.40 (1H, m), 7.19-7.14 (2H, m), 6.97-6.92 (2H, m), 6.89 (1H, d, $J = 0.8$ Hz), 3.84 (3H, s), 2.66 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 161.9, 156.5, 148.0, 147.3, 146.5, 129.5, 128.4, 125.8, 124.4, 123.6, 122.4, 114.6, 112.4, 55.6, 18.9; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 266.1, $\text{C}_{17}\text{H}_{16}\text{NO}_2^+$ requires 266.1.


2-(Phenylthio)-4-(thiophen-3-yl)-7-(trifluoromethyl)quinoline (2ax)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 mmol), benzenethiol (38 μ L, 0.38 mmol), triphenyl(4-(thiophen-3-yl)-7-(trifluoromethyl)quinolin-2-yl)phosphonium trifluoromethanesulfonate (172 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel: 40% DCM in hexanes) afforded the *title compound* (2ax) as a white powder (71 mg, 0.18 mmol, 74% yield). mp: 89-93 $^\circ\text{C}$; IR


$\nu_{\max}/\text{cm}^{-1}$ (film): 3103, 2923, 2852, 2161, 1792, 1586, 1334, 1288, 1156, 1116, 1097, 1062, 829, 769; ^1H NMR (400 MHz, CDCl_3) δ : 8.24 (1H, s), 8.05 (1H, d, $J = 8.7$ Hz), 7.71-7.66 (2H, m), 7.58 (1H, dd, $J = 8.8, 1.8$ Hz), 7.51-7.45 (4H, m), 7.42 (1H, dd, $J = 2.9, 1.2$ Hz), 7.21 (1H, dd, $J = 5.0, 1.2$ Hz), 7.12 (1H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 162.9, 147.8, 143.4, 137.4, 135.2, 131.6 (q, $J = 33.1$ Hz), 129.9, 129.7, 129.5, 128.5, 126.9, 126.7, 126.5 (q, $J = 4.4$ Hz), 126.4, 125.5, 123.9 (q, $J = 272.1$ Hz), 121.3 (q, $J = 3.2$ Hz), 120.8; ^{19}F NMR (365 MHz, CDCl_3) δ : -62.79; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 388.1, $\text{C}_{20}\text{H}_{13}\text{F}_3\text{NS}_2^+$ requires 388.0.

5-bromo-4-(4-methoxyphenoxy)-2-(methylthio)pyrimidine (2ay)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), (5-bromo-2-(methylthio)pyrimidin-4-yl)triphenylphosphonium trifluoromethanesulfonate (307 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 5% EtOAc in hexanes) afforded the *title compound* (2ay) as a white solid (142 mg, 0.44 mmol, 87% yield). mp: 86-88 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3024, 3006, 2926, 2836, 1554, 1537, 1501, 1407, 1332, 1288, 1256, 1221, 1176, 1031, 957, 822, 760; ^1H NMR (400 MHz, CDCl_3) δ : 8.45 (1H, s), 7.11-7.06 (2H, m), 6.94-6.89 (2H, m), 3.83 (3H, s), 2.26 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 170.9, 164.6, 159.4, 157.3, 145.5, 122.5, 114.3, 100.8, 55.6, 14.3; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 327.0, $\text{C}_{12}\text{H}_{12}\text{BrN}_2\text{O}_2\text{S}^+$ requires 327.0.

5-(4-Methoxyphenyl)-4-(phenylthio)pyrimidine (2az)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), benzenethiol (77 μ L, 0.75 mmol), (5-(4-methoxyphenyl)pyrimidin-4-yl)triphenylphosphonium trifluoromethanesulfonate (298 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2az) as a white powder (98 mg, 0.33 mmol, 66% yield). mp: 98-101 $^{\circ}$ C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3074, 3009, 2936, 2835, 2545, 2162, 2061, 1575, 1522, 1509, 1379, 1293, 1252, 1176, 747; ^1H NMR (400 MHz, CDCl_3) δ : 8.76 (1H, s); 8.31 (1H, s), 7.56-7.50 (2H, m), 7.49-7.41 (5H, m), 7.09-7.03 (2H, m), 3.90 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 168.4, 160.2, 156.7, 154.2, 135.6, 132.5, 130.4, 129.5, 129.2, 128.3, 126.6, 114.3, 55.4; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 295.1, $\text{C}_{17}\text{H}_{15}\text{N}_2\text{OS}^+$ requires 295.1.


5-(4-Methoxyphenyl)-4-(1H-pyrrol-1-yl)pyrimidine (2ba)



Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 mmol), 1H-pyrrole (26 μ L, 0.38 mmol), (5-(4-methoxyphenyl)pyrimidin-4-yl)triphenylphosphonium trifluoromethanesulfonate (149 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel: 20% EtOAc in hexanes) afforded the *title compound* (2ba) as a white powder (52 mg, 0.21 mmol, 82% yield). mp: 100-105 $^{\circ}$ C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3158, 3121, 3058, 2924, 2840, 1610, 1578, 1551, 1442, 1393, 1349, 1248, 1178, 1059, 931, 835,


731; ^1H NMR (400 MHz, CDCl_3) δ : 8.98 (1H, d, s), 8.60 (1H, s), 7.24-7.19 (2H, m), 7.04 (2H, t, $J = 2.3$ Hz), 7.00-6.95 (2H, m), 6.18 (2H, t, $J = 2.3$ Hz), 3.87 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 160.0 (2C), 157.1, 154.6, 130.0, 126.8, 124.4, 120.7, 114.7, 111.4, 55.3; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 252.1, $\text{C}_{15}\text{H}_{14}\text{N}_3\text{O}^+$ requires 252.1.

2-(4-Methoxyphenoxy)quinoxaline (2bb)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), 4-methoxyphenol (93 mg, 0.75 mmol), 15-crown-5 (150 μL , 0.75 mmol), triphenyl(quinoxalin-2-yl)phosphonium trifluoromethanesulfonate (270 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography by dissolving in CH_2Cl_2 and dry loading (silica gel: 10% EtOAc in hexanes) afforded the *title compound* (2bb) as a white amorphous solid (100 mg, 0.40 mmol, 79% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3060, 3022, 2953, 2931, 2836, 2599, 2042, 1887, 1830, 1641, 1574, 1499, 1401, 1306, 1251, 1205, 1182, 993, 917, 829, 759; ^1H NMR (400 MHz, CDCl_3) δ : 8.67 (1H, s), 8.05 (1H, dd, $J = 8.0, 1.7$ Hz), 7.78-7.74 (1H, m), 7.68-7.57 (2H, m), 7.23-7.18 (2H, m), 7.00-6.95 (2H, m), 3.86 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 157.2, 156.9, 146.1, 140.0, 139.5, 139.1, 130.2, 128.8, 127.7, 127.2, 122.3, 114.6, 55.5; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 253.2, $\text{C}_{15}\text{H}_{13}\text{N}_2\text{O}_2^+$ requires 253.1.

2-(Bis(3-(trifluoromethyl)phenyl)methyl)-4-(1H-pyrrol-1-yl)pyridine (2bc)



Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.375 mmol), 1*H*-pyrrole (26 μ L, 0.38 mmol), (2-(bis(3-(trifluoromethyl)phenyl)methyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (198 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel, gradient elution: 10% EtOAc in hexanes to 20% EtOAc in hexanes) afforded the *title compound* (2bc) as a yellow oil (52 mg, 0.12 mmol, 46% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 2927, 2251, 1980, 1722, 1595, 1497, 1328, 1165, 1127, 1075, 904, 725; ^1H NMR (400 MHz, CDCl_3) δ : 8.61 (1H, d, $J = 5.5$ Hz), 7.60-7.35 (8H, m), 7.21 (1H, dd, $J = 5.5, 2.2$ Hz), 7.16-7.08 (3H, m), 6.38 (2H, t, $J = 2.1$ Hz), 5.75 (1H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 163.0, 151.4, 147.3, 142.5, 132.6, 131.0 (q, $J = 32.2$ Hz), 129.2, 125.9 (q, $J = 3.8$ Hz), 124.0 (q, $J = 3.7$ Hz), 124.0 (q, $J = 272.8$ Hz), 118.3, 113.5, 112.4, 111.9, 58.7; ^{19}F NMR (365 MHz, CDCl_3) δ : -62.57; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 447.1, $\text{C}_{24}\text{H}_{17}\text{F}_6\text{N}_2^+$ requires 447.1.


(2R,6S)-4-((2-(1*H*-Imidazol-1-yl)quinolin-4-yl)methyl)-2,6-dimethylmorpholine (2bd)



Prepared according to general procedure D using potassium hydride (36.3% dispersion in mineral oil, 41 mg, 0.38 mmol), 1*H*-imidazole (26 mg, 0.38 mmol), (4-(((2R,6S)-2,6-dimethylmorpholino)methyl)quinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate (167 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel: 4% MeOH in DCM) afforded the *title compound* (2bd) as a white amorphous solid (52 mg, 0.16 mmol, 64% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3150, 3127, 2974, 2931, 2877, 2811, 2773, 2205, 1660, 1599, 1432, 1325, 1084, 1058, 931, 721, 651; ^1H NMR (400 MHz, CDCl_3) δ : 8.51 (1H, s), 8.19 (1H, dd, $J = 8.4, 0.7$ Hz), 8.04 (1H, dd, $J = 8.4$ Hz, 0.5 Hz), 7.86 (1H,


m), 7.77-7.71 (1H, m), 7.61 (1H, s), 7.57-7.51 (1H, m), 7.25 (1H, m), 3.94 (2H, s), 3.78-3.69 (2H, m), 2.75 (2H, d, $J = 10.3$ Hz), 1.94 (2H, t, $J = 10.5$ Hz), 1.16 (6H, d, $J = 6.3$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 148.1, 147.4, 147.3, 135.3, 130.7, 130.5, 129.3, 126.3, 126.2, 124.0, 116.5, 111.5, 71.7, 59.7, 59.4, 19.1; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 323.2, $\text{C}_{19}\text{H}_{23}\text{N}_4\text{O}^+$ requires 323.2.

2-Methyl-4-(4-((4-(phenylthio)pyridin-3-yl)methyl)piperazin-1-yl)quinoline (2be)




Prepared according to general procedure C sodium hydride (60% dispersion in mineral oil, 6 mg, 0.15 mmol), benzenethiol (16 μL , 0.15 mmol), (3-((4-(2-methylquinolin-4-yl)piperazin-1-yl)methyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (73 mg, 0.10 mmol) and DME (0.4 mL). Flash column chromatography (silica gel, gradient elution: 100% EtOAc to 1% NEt₃ in EtOAc) afforded the *title compound* (2be) as an orange oil (15 mg, 0.034 mmol, 34% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3061, 2933, 2825, 2361, 2340, 2205, 1589, 1574, 1416, 1283, 1192, 1136, 1006, 905, 726; ^1H NMR (400 MHz, CDCl_3) δ : 8.44 (1H, s), 8.22 (1H, d, $J = 5.4$ Hz), 7.98 (2H, t, $J = 7.7$ Hz), 7.65-7.58 (1H, m), 7.56-7.51 (2H, m), 7.48-7.39 (4H, m), 6.75 (1H, s), 6.71 (1H, d, $J = 5.4$ Hz), 3.75 (2H, s), 3.33-3.17 (4H, m), 3.87-3.78 (4H, m), 2.68 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 159.4, 157.0, 151.0, 149.6, 149.2, 148.6, 135.1, 131.2, 130.5, 129.9, 129.4, 129.2, 129.0, 124.5, 123.5, 121.9, 121.4, 109.5, 58.4, 52.7, 52.1, 25.6; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 427.4, $\text{C}_{26}\text{H}_{27}\text{N}_4\text{S}^+$ requires 427.2.

4''-(Phenylthio)-3'-(trifluoromethyl)-2,2':5',3''-terpyridine (2bf)



Prepared according to general procedure C sodium hydride (60% dispersion in mineral oil, 30 mg, 0.75 mmol), benzenethiol (77 μ L, 0.75 mmol), triphenyl(3'-(trifluoromethyl)-[2,2':5',3''-terpyridin]-4''-yl)phosphonium trifluoromethanesulfonate (356 mg, 0.50 mmol) and THF (1.0 mL). Flash column chromatography (silica gel: 100% EtOAc) followed by a second flash column (20% EtOAc, 10% NEt₃ in hexanes) afforded the *title compound* (2bf) as a yellow amorphous solid (132 mg, 0.32 mmol, 65% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3060, 2925, 2227, 1569, 1448, 1429, 1331, 1285, 1162, 1138, 1019, 906, 727, 689; ¹H NMR (400 MHz, CDCl₃) δ : 8.98 (1H, d, J = 1.9 Hz), 8.76 (1H, d, J = 4.8 Hz), 8.40 (1H, s), 8.37 (1H, d, J = 5.5 Hz), 8.28 (1H, d, J = 2.0 Hz), 7.88 (1H, td, J = 7.8, 1.8 Hz), 7.80-7.76 (1H, m), 7.55-7.39 (6H, m), 6.80 (1H, d, J = 5.4 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 156.5, 156.1, 151.8, 149.8, 149.8, 149.4, 149.1, 136.5, 136.2 (q, J = 5.0 Hz), 135.4, 132.0, 130.2, 130.0, 129.8, 128.9, 125.0 (q, J = 33.0 Hz), 123.4 (q, J = 273.1 Hz), 123.8, 123.7, 120.7; ¹⁹F NMR (365 MHz, CDCl₃) δ : -57.64 ; m/z LRMS (ESI + APCI) found [M+H]⁺ 410.2, C₂₂H₁₅F₃N₃S⁺ requires 410.1.


N-Methyl-N-phenyl-2-((pyridin-3-ylmethyl)thio)pyrimidin-4-amine (2bg)



Prepared according to general procedure E using n-butyl lithium (1.6 M in hexanes, 234 μ L, 0.38 mmol), *N*-methylaniline (40.6 μ L, 0.38 mmol), triphenyl(2-((pyridin-3-

ylmethylthio)pyrimidin-4-yl)phosphonium trifluoromethanesulfonate (153 mg, 0.25 mmol) and THF (1.0 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt₃: 15% EtOAc in toluene) afforded the *title compound* (2bg) as a yellow oil (29 mg, 0.093 mmol, 37% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3035, 2927, 2224, 1710, 1600, 1568, 1498, 1348, 1200, 975, 904, 726, 647; ¹H NMR (400 MHz, CDCl₃) δ : 8.64 (1H, d, J = 1.8 Hz), 8.47 (1H, dd, J = 1.5, 4.9 Hz), 7.87 (1H, d, J = 6.1 Hz), 7.77-7.72 (1H, m), 7.48-7.41 (2H, m), 7.35-7.30 (1H, m), 7.25-7.19 (3H, m), 5.99 (1H, d, J = 6.0 Hz), 4.36 (2H, s), 3.44 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ : 169.7, 161.7, 154.9, 150.2, 148.3, 144.1, 136.3, 134.5, 130.0, 127.3, 126.9, 123.3, 100.9, 37.9, 32.1; m/z LRMS (ESI + APCI) found $[M+H]^+$ 309.2, C₁₇H₁₇N₄S⁺ requires 309.1.


5-(((4-(4-Methoxyphenoxy)pyrimidin-2-yl)oxy)methyl)-3-phenylisoxazole (2bh)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.375 mmol), 4-methoxyphenol (47 mg, 0.38 mmol), 15-crown-5 (74 μ L, 0.38 mmol), triphenyl(2-((3-phenylisoxazol-5-yl)methoxy)pyrimidin-4-yl)phosphonium trifluoromethanesulfonate (166 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel, gradient elution: 4% EtOAc in toluene to 8% EtOAc in toluene) afforded the *title compound* (2bh) as a clear oil (52 mg, 0.14 mmol, 55% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3053, 2917, 2848, 2247, 1610, 1574, 1504, 1441, 1272, 1244, 1193, 1080, 905, 726, 693; ¹H NMR (400 MHz, CDCl₃) δ : 8.36 (1H, d, J = 5.6 Hz), 7.80-7.74 (2H, m), 7.47-7.42 (3H, m), 7.10-7.04 (2H, m), 6.96-6.90 (2H, m), 6.53 (1H, d, J = 5.6 Hz), 6.51 (1H, s), 5.42 (2H, s), 3.82


(3H, s); ^{13}C NMR (100 MHz, CDCl_3)
 δ : 171.6, 167.9, 164.2, 162.4, 160.3, 157.4, 145.5, 130.0, 128.9, 126.8, 122.4, 114.8, 102.3, 102.2, 101.8, 59.7, 55.6; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 376.2, $\text{C}_{21}\text{H}_{18}\text{N}_3\text{O}_4^+$ requires 376.1.

4-(4-Methoxyphenoxy)-2-((1-(4-phenoxyphenoxy)propan-2-yl)oxy)pyridine (2bi)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.375 mmol), 4-methoxyphenol (47 mg, 0.38 mmol), 15-crown-5 (74 μL , 0.38 mmol), (2-((1-(4-phenoxyphenoxy)propan-2-yl)oxy)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (183 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel: 10% EtOAc in hexanes) afforded the *title compound* (2bi) as a clear oil (56 mg, 0.13 mmol, 50% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3042, 2932, 2836, 2578, 2250, 2050, 1594, 1502, 1488, 1472, 1218, 1203, 1147, 906, 839, 728; ^1H NMR (400 MHz, CDCl_3) δ : 7.99 (1H, d, $J = 5.9$ Hz), 7.34-7.27 (2H, m), 7.08-6.99 (3H, m), 6.99-6.88 (8H, m), 6.52 (1H, dd, $J = 5.9, 2.2$ Hz), 6.12 (1H, d, $J = 2.2$ Hz), 5.56 (1H, m), 4.18-4.10 (1H, m), 4.08-4.01 (1H, m), 3.82 (3H, m), 1.45 (3H, d, $J = 6.4$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 167.8, 165.0, 158.5, 157.1, 155.2, 150.3, 147.8, 147.3, 129.6, 122.4, 122.1, 120.7, 117.6, 115.8, 115.1, 107.0, 97.4, 71.0, 69.6, 55.6, 17.0; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 444.2, $\text{C}_{27}\text{H}_{26}\text{NO}_5^+$ requires 444.2.

(6R,10S)-8-Benzyl-2-(4-methoxyphenoxy)-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2bj)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 6 mg, 0.15 mmol), 4-methoxyphenol (19 mg, 0.15 mmol), 15-crown-5 (30 μ L, 0.15 mmol), ((6R,10S)-8-benzyl-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxalin-2-yl)triphenylphosphonium trifluoromethanesulfonate (71 mg, 0.10 mmol) and THF (0.2 mL). Flash column chromatography (silica gel: 30% EtOAc in hexanes) afforded the *title compound* (2bj) as a yellow oil (24 mg, 0.057 mmol, 57% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3016, 2950, 1836, 2791, 2162, 2049, 1568, 1503, 1347, 1290, 1202, 907, 667; ^1H NMR (400 MHz, CDCl_3) δ : 8.59 (1H, s), 7.73 (1H, s), 7.50 (1H, s), 7.24-7.19 (2H, m), 7.14-7.09 (3H, m), 7.00-6.94 (2H, m), 6.88-6.81 (2H, m), 3.85 (3H, s), 3.46 (2H, s), 3.33-3.21 (2H, m), 2.98-2.87 (2H, m), 2.52 (2H, t, J = 8.3 Hz), 2.34-2.25 (1H, m), 1.81 (1H, d, J = 10.6 Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 156.9, 156.8, 151.1, 147.8, 146.6, 140.1, 139.6, 138.3, 136.6, 128.3, 128.0, 126.6, 122.3, 120.2, 119.3, 114.6, 61.6, 57.3, 57.2, 55.6, 43.4, 41.4, 41.1; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 424.2, $\text{C}_{27}\text{H}_{26}\text{N}_3\text{O}_2^+$ requires 424.2.

Ethyl 4-(8-chloro-4-(phenylthio)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate (2bk)




Prepared according to general procedure C sodium hydride (60% dispersion in mineral oil, 12 mg, 0.30 mmol), benzenethiol (31 μ L, 0.30 mmol), (8-chloro-11-(1-(ethoxycarbonyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (159 mg, 0.20 mmol) and THF (0.40 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt_3 , gradient elution: 60% CH_2Cl_2 in hexanes to 70% CH_2Cl_2 in hexanes to 10 % MeOH in CH_2Cl_2) followed by a second flash column (silica gel was packed with hexanes and neutralized with NEt_3 , gradient elution: 9.5% CH_2Cl_2 , 0.5% NEt_3 in toluene to 8% CH_2Cl_2 , 2% NEt_3 in toluene) afforded the *title compound* (2bk) as a white solid (82 mg, 0.17 mmol, 83% yield). 198-201 $^\circ\text{C}$; IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3055, 2977, 2918, 2862, 2360, 2339, 2049, 1693, 1546, 1430, 1222, 1109, 748; ^1H NMR (400 MHz, CDCl_3) δ : 8.08 (1H, d, J = 5.4 Hz), 7.54-7.42 (5H, m), 7.21 (1H, d, J = 1.9 Hz), 7.18-7.09 (2H, m), 6.44 (1H, d, J = 5.4 Hz), 4.14 (2H, q, J = 7.2 Hz), 3.90-3.70 (2H, br), 3.50-3.40 (1H, m), 3.28-3.10 (3H, m), 3.04-2.83 (2H, m), 2.54-2.43 (1H, m), 2.40-2.27 (3H, m), 1.25 (3H, t, J = 7.1 Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 159.2, 155.5, 150.4, 146.1, 139.7, 137.9, 137.7, 135.6, 134.1, 133.0, 130.2, 130.0, 129.8, 129.5, 129.1, 128.7, 126.2, 118.8, 61.3, 44.7, 30.9, 30.6, 28.9, 14.7; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 491.2, $\text{C}_{28}\text{H}_{28}\text{ClN}_2\text{O}_2\text{S}^+$ requires 491.2.

Ethyl 4-((4-chlorophenyl)(4-(phenylselenanyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate (2bl)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 mmol), benzeneselenol (40 μ L, 0.38 mmol), (2-((4-chlorophenyl)((1-(ethoxycarbonyl)piperidin-4-yl)oxy)methyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (196 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel: 30% EtOAc in toluene) afforded the *title compound* (2bl) as a clear oil (93 mg, 0.18 mmol, 70% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3289, 3049, 2927, 2667, 2349, 2245, 1690, 1567, 1226, 1085, 1014; ^1H NMR (400 MHz, CDCl_3) δ : 8.20 (1H, d, J = 5.2 Hz), 7.65-7.60 (2H, m), 7.48-7.36 (3H, m), 7.32 (1H, d, J = 1.5 Hz), 7.30-7.23 (4H, m), 6.96 (1H, dd, J = 5.3, 1.7 Hz), 5.47 (1H, s), 4.13 (2H, q, J = 7.2 Hz), 3.65-3.50 (3H, m), 3.25-3.14 (2H, m), 1.80-1.70 (1H, m), 1.70-1.46 (3H, m), 1.26 (3H, t, J = 7.0 Hz); ^{13}C NMR (100 MHz, CDCl_3) δ : 161.7, 155.5, 148.7, 147.2, 139.8, 136.5, 133.5, 129.9, 129.5, 128.6, 128.2, 126.1, 122.5, 120.3, 80.6, 73.3, 61.3, 40.8 (rot), 31.0 (rot), 30.7, 14.7; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 531.2, $\text{C}_{26}\text{H}_{28}\text{ClN}_2\text{O}_3\text{Se}^+$ requires 531.1.

(1S,2R,4S,5R)-2-((R)-2-(1H-Pyrrol-1-yl)quinolin-4-yl)(benzyloxy)methyl)-5-vinylquinuclidine (2bm)




Prepared according to general procedure D using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.38 mmol), 1H-pyrrole (26 μ L, 0.38 mmol), (4-((R)-(benzyloxy)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methyl)quinolin-2-yl)triphenylphosphonium trifluoromethanesulfonate (199 mg, 0.25 mmol) and THF (0.5 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt₃: 80% EtOAc in hexanes) followed by another flash column (silica gel, gradient elution: 100% EtOAc to 5% NEt₃ in EtOAc) afforded the *title compound* (2bm) as white solid (61 mg, 0.14 mmol, 54% yield). mp: 70-76 °C; IR ν_{max} /cm⁻¹ (film): 3149, 3064, 3030, 2932, 2862, 1635, 1599, 1479, 1357, 1256, 1066, 959, 731, 695; ¹H NMR (400 MHz, CDCl₃) δ : 8.09-8.02 (2H, m), 7.75-7.63 (4H, m), 7.54-7.47 (1H, m), 7.41-7.30 (5H, m), 6.40 (2H, t, J = 2.2 Hz), 5.80-5.66 (1H, m), 5.32 (1H, br), 4.99-4.85 (2H, m), 4.48 (2H, s), 3.48-3.34 (1H, m), 3.20-3.05 (2H, m), 2.77-2.58 (2H, m), 2.32-2.22 (1H, m), 1.86-1.46 (5H, m); ¹³C NMR (100 MHz, CDCl₃) δ : 149.8, 149.7, 147.8, 141.9, 137.7, 130.0, 129.5, 128.6, 127.9, 127.8, 127.6, 125.6, 124.6, 123.1 (br), 118.5, 114.3, 111.6, 108.8 (br), 71.6, 60.8, 57.1, 43.3, 40.0, 27.9, 27.8, 22.7 (br); *m/z* LRMS (ESI + APCI) found [M+H]⁺ 450.3, C₃₀H₃₂N₃O⁺ requires 450.3.

(3S,8R,9S,10R,13S,14S)-17-(4-((3-Methoxyphenyl)thio)pyridin-3-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate (2bn)




Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 11 mg, 0.28 mmol), 3-methoxybenzenethiol (34 μ L, 0.28 mmol), (3-((3S,8R,9S,10R,13S,14S)-3-acetoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (120 mg, 0.15 mmol) and THF (0.3 mL). Flash column chromatography (basic alumina, gradient elution: 20% EtOAc in hexanes to 30% EtOAc in hexanes) afforded the *title compound* (2bn) as a clear oil (49 mg, 0.092 mmol, 61% yield). IR $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 3246, 3032, 2935, 2797, 2361, 2341, 2162, 1655, 1571, 1446, 1402, 1282, 1162, 1010, 814, 726; ^1H NMR (400 MHz, CDCl_3) δ : 8.20 (1H, s), 8.14 (1H, d, $J = 5.0$ Hz), 7.35 (1H, t, $J = 8.0$ Hz), 7.11-7.07 (1H, m), 7.05-7.02 (1H, m), 7.00-6.95 (1H, m), 6.65 (1H, d, $J = 5.3$ Hz), 5.97-5.93 (1H, m), 5.43 (1H, d, $J = 4.9$ Hz), 4.68-4.57 (1H, m), 3.82 (3H, s), 2.42-2.31 (3H, m), 2.20-2.00 (6H, m), 1.92-1.81 (2H, m), 1.77-1.52 (7H, m), 1.15-1.00 (8H, m); ^{13}C NMR (100 MHz, CDCl_3) δ : 170.5, 160.4, 157.5, 155.0, 150.3, 149.6, 148.2, 147.7, 140.0, 132.9, 131.8, 130.7, 127.5, 122.3, 120.3, 115.4, 73.9, 56.9, 55.4, 50.4, 49.7, 38.1, 36.9, 36.8, 34.7, 32.3, 31.6, 30.7, 27.7, 21.4, 20.7, 19.3, 16.5; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 530.3, $\text{C}_{33}\text{H}_{40}\text{NO}_3\text{S}^+$ requires 530.3.

N-(4-((5-Chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-4'-yl)oxy)phenyl)acetamide (2bo)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 15 mg, 0.375 mmol), N-(4-hydroxyphenyl)acetamide (57 mg, 0.38 mmol), 15-crown-5 (74 μ L, 0.38 mmol), (5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-[2,3'-bipyridin]-4'-yl)triphenylphosphonium trifluoromethanesulfonate (192 mg, 0.25 mmol) and DME (0.5 mL). Flash column chromatography (silica gel, gradient elution: 3% MeOH in DCM to 5% MeOH in DCM) afforded the *title compound* (2bo) as a clear oil (49 mg, 0.12 mmol, 48% yield). IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3317, 3062, 2929, 2252, 1980, 1676, 1599, 1504, 1313, 1151, 904, 725; ^1H NMR (400 MHz, CDCl_3) δ : 8.76 (1H, d, $J = 2.3$ Hz), 8.66 (1H, s), 7.84-7.79 (2H, m), 7.72 (1H, d, $J = 2.3$ Hz), 7.41-7.33 (4H, m), 7.20-7.14 (1H, br), 6.24-6.18 (3H, m), 3.09 (3H, s), 2.43 (3H, s), 2.17 (3H, s); ^{13}C NMR (100 MHz, CDCl_3) δ : 168.8, 162.6, 160.0, 150.0, 148.7, 148.4, 148.0, 144.1, 140.2, 137.3, 136.2, 132.0, 129.6, 127.7, 123.1, 121.6, 120.4, 109.5, 69.1, 44.3, 24.3, 23.4; m/z LRMS (ESI + APCI) found $[\text{M}+\text{H}]^+$ 508.1, $\text{C}_{26}\text{H}_{23}\text{ClN}_3\text{O}_4\text{S}^+$ requires 508.1.


N-(3-((4-(4-((3-Methoxyphenyl)thio)pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylphenyl)-4-methylpiperazin-1-yl)methyl)benzamide (2bp)



Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 6 mg, 0.15 mmol), 3-methoxybenzenethiol (19 μ L, 0.15 mmol), 3-(2-((2-methyl-5-(4-((4-methylpiperazin-1-yl)methyl)benzamido)phenyl)amino)pyrimidin-4-yl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (90 mg, 0.10 mmol) and THF (0.2 mL). Flash column chromatography (silica gel was packed with hexanes and neutralized with NEt₃: 4% MeOH in DCM) afforded the *title compound* (2bp) as a yellow solid (40 mg, 0.063 mmol, 57% yield, 6% regioisomer) mp: 78-84 °C; IR $\nu_{\max}/\text{cm}^{-1}$ (film): 3246, 3032, 2935, 2797, 2361, 2341, 2162, 1655, 1571, 1446, 1402, 1282, 1162, 1010, 814, 726; ¹H NMR (400 MHz, CDCl₃) δ : 8.69 (1H, s), 8.56 (1H, d, J = 5.1 Hz), 8.35 (1H, d, J = 2.1 Hz), 8.29 (1H, d, J = 5.5 Hz), 7.86 (1H, s), 7.77 (2H, d, J = 8.2 Hz), 7.58 (1H, dd, J = 8.1, 1.6 Hz), 7.41 (2H, d, J = 8.2 Hz), 7.31-7.19 (3H, m), 7.09 (1H, d, J = 5.1 Hz), 7.07-7.04 (1H, m), 7.02-7.00 (1H, m), 6.95 (1H, dd, J = 8.3, 2.4 Hz), 6.78 (1H, d, J = 5.5 Hz), 3.75 (3H, s), 3.56 (2H, s), 2.60-2.41 (8H, br), 2.35 (3H, s), 2.30 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ : 165.3, 163.6, 160.5, 160.0, 158.8, 150.2, 149.8, 149.5, 142.5, 137.4, 136.6, 133.8, 131.4, 131.0, 130.9, 130.8, 129.2, 127.6, 127.0, 124.5, 121.3, 120.2, 116.0, 115.8, 113.6, 111.4, 62.5, 55.4,

55.1, 53.1, 46.0, 17.6; m/z LRMS (ESI + APCI) found $[M+H]^+$ 632.4, $C_{36}H_{38}N_7O_2S^+$ requires 632.3.

Methyl 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-5-cyclopropylpicolinate (2bq)





Prepared according to general procedure C using sodium hydride (60% dispersion in mineral oil, 11 mg, 0.275 mmol), 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-hydroxyphenyl)urea (67.1 mg, 0.203 mmol), 15-Crown-5 (40.3 μ L, 0.203 mmol), (5-cyclopropyl-2-(methoxycarbonyl)pyridin-4-yl)triphenylphosphonium trifluoromethanesulfonate (79.3 mg, 0.14 mmol) and DME (0.27 mL). Flash column chromatography (silica: 70% EtOAc in hexanes) followed by a second flash column (silica, gradient elution: 85% EtOAc, 5% NEt_3 in hexanes to 100% EtOAc) afforded the *title compound* (2bq) as an off-white amorphous solid (28 mg, 0.055 mmol, 40% yield). IR ν_{max}/cm^{-1} (film): 3350, 3310, 3125, 3082, 2957, 1731, 1710, 1599, 1552, 1504, 1482, 1418, 1301, 1229, 1203, 1173, 1110, 984, 831, 733; 1H NMR (400 MHz, $CDCl_3$) δ : 9.24 (1H, s), 9.00 (1H, s), 8.28 (1H, s), 8.12 (1H, d, $J = 2.2$ Hz), 7.69-7.55 (4H, m), 7.20-7.13 (3H, m), 3.78 (3H, s), 2.27-2.18 (1H, m), 1.12-1.05 (2H, m), 1.00-0.94 (2H, m); ^{13}C NMR (100 MHz, $(CD_3)_2SO$) δ : 164.8, 163.6, 152.5, 148.4, 147.7, 146.3, 139.3, 136.8, 132.0, 131.8, 126.7 (q, $J = 30.2$ Hz), 123.1, 122.8 (q, $J = 272.2$ Hz), 122.3 (q, $J = 1.8$ Hz), 121.2, 120.6, 116.8 (q, $J = 5.4$ Hz), 110.0, 52.3, 8.3, 8.0; ^{19}F NMR (365 MHz, $(CD_3)_2SO$) δ : -62.76; m/z LRMS (ESI + APCI) found $[M+H]^+$ 506.1, $C_{24}H_{20}ClF_3N_3O_4^+$ requires 506.1.


8. References


- S1.** D. D. Perrin, W. L. F. Amarego, Purification of Laboratory Chemicals (Pergamon, Press, Oxford. ed. 3, 1988).
- S2.** Hilton, M.; Dolewski, R.; McNally, A. Selective Functionalization of Pyridines via Heterocyclic Phosphonium Salts. *J. Am. Chem. Soc.*, 2016, 138 (42), pp 13806–13809.
- S3.** Patel, C.; Mohnike, M.C.; Hilton, M.C.; McNally, A. A Strategy to Aminate Pyridines, Diazines and Pharmaceuticals via Heterocyclic Phosphonium Salts, *Org. Lett.*, 2018, doi.org/10.1021/acs.orglett.8b00813
- S4.** Zhang, X.; McNally, A. Phosphonium Salts as Pseudohalides: Regioselective Nickel-Catalyzed Cross-Coupling of Complex Pyridines and Diazines, *Angew. Chem. Int. Ed.*, 2017, doi-org.ezproxy2.library.colostate.edu/10.1002/anie.201704948
- S5.** Anderson, R.; Jett, B.; McNally, A. Selective Formation of Heteroaryl Thioethers via a Phosphonium Ion Coupling Reaction. *Tetrahedron*, 2017, <https://doi.org/10.1016/j.tet.2017.12.040>
- S6.** Koniarczyk, J.; Hesk, D.; Overgard, A.; Davies, I.W.; McNally, A. A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines and Pharmaceuticals, *J. Am. Chem. Soc.*, 2018, doi.org/10.1021/jacs.7b11710
- S7.** Dolewski, R.D.; Fricke, P.J.; McNally, A. Site-Selective Switching Strategies to Functionalize Polyazines, *J. Am. Chem. Soc.*, 2018, doi.org/10.1021/jacs.8b04530

CDCl₃, 400 MHz




S80








CDCl₃, 365 MHz




S82







CDCl₃, 100 MHz



150.0
148.3
143.6
129.9
129.1
127.6
126.3
124.2
121.4


77.3
77.0
76.7
71.6

59.6


19.0

S86

200 192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 ppm




S88




-61.46


(CD₃)₂SO, 365 MHz



689

0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 ppm







— -63.08

— -78.20


CDCl₃, 365 MHz




S92




CDCl₃, 162 MHz




—15.62




S93




S94



CDCl₃, 365 MHz





— -78.17





S96


CDCl₃, 162 MHz




S97








CDCl₃, 162 MHz




— 14.47



S101


CDCl₃, 400 MHz



7.95
7.94
7.94
7.93
7.93
7.92
7.92
7.92
7.91
7.91
7.84
7.84
7.83
7.83
7.82
7.81
7.81
7.80
7.79
7.79
7.78
7.78
7.77
7.75
7.75
7.36
7.32
7.26

3.22
3.20
3.19

1.28
1.26



9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm

0.88

3.04

12.27



1.00

1.01

6.13


S102

CDCl₃, 100 MHz




S103

CDCl₃, 365 MHz




— -78.22




S104


CDCl₃, 162 MHz





—23.07



S105




CDCl₃, 100 MHz




S107

CDCl₃, 365 MHz




-78.20




S108


CDCl₃, 162 MHz




— 16.36

S109









— -78.17


CDCl₃, 365MHz



S112





CDCl₃, 162 MHz



—22.15


S113






S114

CDCl₃, 100 MHz




2a

166.3
159.5
157.1
151.1
147.4
139.2
129.1
128.7
126.9
122.0
115.2
110.2
108.5
77.3
77.0
76.7
55.7







S115

Crude ^{31}P NMR
 CDCl_3 , 365 MHz




2a





S117

CDCl₃, 100 MHz




2b

— 165.6
— 159.7
— 154.2
— 151.2


— 139.1
— 130.2
— 129.1
— 128.7
— 126.9
— 125.3
— 120.7

— 110.7
— 109.1


— 77.3
— 77.0
— 76.7



S118




CDCl₃, 100 MHz




2c

165.0
159.8
154.3
151.3
139.2
138.9
129.3
128.7
126.9
122.8
110.8
109.2
88.8
77.3
77.0
76.7




S120



S121

CDCl₃, 100 MHz





2d

— 165.7
— 159.4
< 151.7
< 150.9
— 142.2
— 139.3
< 129.0
< 128.6
< 126.9
< 126.7
< 122.7
< 121.3
— 113.0
— 109.6
— 108.2


< 77.3
< 77.0
< 76.7

— 55.9






CDCl₃, 100 MHz




2e


— 165.8
— 159.7
— 153.7
— 151.2
— 147.6
— 139.0
— 129.2
— 128.7
— 127.0
— 126.2
— 120.8
— 112.5
— 112.2
— 110.2
— 108.6
— 77.3
— 77.0
— 76.7
— 56.7



S124



CDCl₃, 100 MHz





2f

— 165.9
— 159.5
< 151.7
 151.1
< 139.3
 134.3
 130.6
 129.1
 128.7
 127.0
 120.9
 117.9
 110.5
 109.0

< 77.3
 77.0
 76.7


< 29.5
 28.9
 23.1
 22.9






S127


CDCl₃, 100 MHz






2g

168.3
165.7
159.7
151.2
150.3
139.0
135.3
129.2
128.7
127.0
121.7
121.4
110.5
108.9
77.3
77.0
76.7
24.5











CDCl₃, 100 MHz




2i

157.4
150.8
149.4
139.0
135.0
129.9
129.7
129.6
129.1
128.7
126.9
119.4
117.8


77.3
77.0
76.7



S132




CDCl₃, 100 MHz




2j

157.6
150.0
149.5
138.9
136.1
136.0
130.2
129.2
128.8
128.4
126.9
119.4
117.9


77.3
77.0
76.7




S134



S136




CDCl₃, 365 MHz





2k

-110.25

S137









21

CDCl₃, 100 MHz




S139




S140


CDCl₃, 100 MHz




2m

159.9
157.2
150.1
149.1
139.2
137.2
131.9
129.0
128.7
126.9
121.6
119.1
117.6
117.0
111.7
77.4
77.0
76.7
56.0







CDCl₃, 100 MHz



157.7
149.6
148.4
138.9
136.5
134.1
131.7
131.0
129.6
129.2
128.7
128.6
127.0
119.9
118.5


77.3
77.0
76.7





S144

CDCl₃, 100 MHz




2o

160.5
157.5
150.6
149.4
139.0
130.8
130.7
129.1
128.7
127.1
126.9
119.8
119.5
118.0
115.7


77.3
77.0
76.7

55.5



S145

7.50
7.50
7.49
7.49
7.48
7.48
7.47
7.47
7.47
7.45
7.45
7.43
7.43
7.43
7.42
7.42
7.41
7.41
7.41
7.40
7.39
7.39
7.39
7.33
7.32
7.32
7.32
7.32
7.31
7.31
7.30
7.30
7.30
7.30
7.29
7.26
6.94
6.93
6.92
6.92




9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm

1.00
2.08
7.34
1.04
0.99

S146


CDCl₃, 100 MHz



2p


157.8
149.8
149.7
149.0
138.8
132.6
132.5
131.0
129.3
128.8
126.9
126.6
124.2
121.8
121.7
119.9
119.1
118.5
116.5

77.3
77.0
76.7



S147

CDCl₃, 365 MHz




2p


-57.88

0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 ppm

S148



CDCl₃, 100 MHz





2q

157.3
150.3
149.3
144.1
139.1
130.2
129.0
128.8
128.7
127.6
126.9
118.0
116.6

77.3
77.0
76.7


21.7





S151


CDCl₃, 100 MHz



2r

157.5
151.5
149.4
139.0
137.9
132.9
129.1
128.7
128.5
127.0
126.5
118.2
116.7


77.3
77.0
76.7



S152

7.87
7.87
7.86
7.85
7.69
7.69
7.68
7.67
7.67
7.58
7.58
7.48
7.48
7.47
7.46
7.46
7.45
7.45
7.44
7.42
7.41
7.40
7.40
7.39
7.38
7.38
7.37
7.26
7.05
7.04
7.03
7.03

CDCl₃, 400 MHz




2s

S153

9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm

1.00
2.06
1.96
1.04
6.14
0.99


CDCl₃, 100 MHz




2s


157.5
149.4
146.2
138.9
136.1
129.9
129.3
129.1
128.7
126.9
126.5
122.4
120.9

77.3
77.0
76.7





S154







S156









S159







CDCl₃, 100 MHz



2x




S162




S163


CDCl₃, 100 MHz




2y




S164




CDCl₃, 100 MHz




2z




S166




CDCl₃, 100 MHz




2ab



S168




CDCl₃, 100 MHz




2ac


159.4
151.0
146.8
142.4
138.8
129.4
128.8
127.1
126.7
110.9
109.5
109.0
77.3
77.0
76.7




S170




S171



S172




CDCl₃, 100 MHz




2ae

159.0
150.6
150.6
147.5
139.9
138.9
129.3
128.8
127.0
115.4
114.1
109.3
77.3
77.0
76.7
13.6
13.3




8.79
8.77
8.11
8.05
8.03
7.87
7.85
7.76
7.75
7.71
7.54
7.53
7.51
7.50
7.50
7.49
7.48
7.47
7.46
7.45
7.43
7.41
7.33
7.31
7.30
7.30
7.26

CDCl₃, 400 MHz



2af




9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm


1.00
1.04
2.08
2.17
1.03
1.07
5.36
2.09

S175


CDCl₃, 100 MHz




2af




S176




CDCl₃, 100 MHz




2ag



S178




S179




8.37
8.26
8.24
7.52
7.51
7.51
7.51
7.50
7.49
7.49
7.48
7.48
7.47
7.47
7.45
7.45
7.44
7.44
7.43
7.42
7.41
7.41
6.68
6.67

CDCl₃, 400 MHz




2ai



S181


CDCl₃, 100 MHz



2ai


149.3
149.2
148.3
136.7
135.6
134.8
130.0
129.9
129.7
129.4
128.5
128.4
120.0

77.3
77.0
76.7





S182

CDCl₃, 400 MHz
Crude ¹H NMR




S183






CDCl₃, 100 MHz




2ak


164.5
152.3
146.4
135.2
129.8
129.6
129.5
114.8
107.2
77.3
77.0
76.7
53.4




S185




CDCl₃, 100 MHz



2a1




S187




S188

CDCl₃, 100 MHz





2am

158.0
155.5
150.6
149.2
147.4
137.0
124.1
121.3
118.5
113.2
112.1
110.5
77.3
77.0
76.7




S189




S190


CDCl₃, 100 MHz




164.7
157.0
149.0
146.6
141.8
141.4
123.9
122.4
121.2
114.9
113.7
113.6
107.7
107.6
107.6
107.5
77.3
77.2
77.0
76.7
55.6




S191




— 64.92




S192



CDCl₃, 100 MHz




2ao



-64.98


CDCl₃, 365 MHz




2ao

S195


0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 ppm



CDCl₃, 400 MHz
(Crude ¹H NMR)




2ap




S197

CDCl₃, 100 MHz




2ap



S198

CDCl₃, 365 MHz




2ap

-64.96




S199

0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 ppm




CDCl₃, 100 MHz




2aq

150.5
149.9
141.6
141.3
135.1
131.4
123.6
120.9
117.6
117.5
117.5
117.5
116.0
108.2
108.1
77.3
77.0
76.7



S201

CDCl₃, 365 MHz






2aq

— -64.90


S202

0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 ppm







S204




2ar






CDCl₃, 100 MHz




2as

153.1
152.9
148.0
135.5
135.4
132.3
131.7
129.4
128.4
128.3
126.1
125.7
115.1
114.1


77.3
77.0
76.7



S207




S208




2at

CDCl₃, 365 MHz




S209




2at

CDCl_3 , 100 MHz



CDCl₃, 400 MHz




2au

8.05
8.04
7.53
7.52
7.51
7.50
7.46
7.45
7.44
7.44
7.43
7.26
6.41
6.40


2.91
2.73

1.90
1.89
1.88
1.87



S211

CDCl₃, 100 MHz




2au


— 156.6
— 149.5
— 146.1
— 135.4
— 130.0
— 129.9
— 129.4
— 128.6
— 117.7

— 77.3
— 77.0
— 76.7

— 32.9
— 26.1
— 22.8
— 22.6




S212





S213



CDCl₃, 100 MHz





2av

















— -62.79




S219






S220






S222





S224

CDCl₃, 100 MHz




2ba

160.0
157.1
154.6


130.0
126.8
124.4
120.7
114.7
111.4


77.3
77.0
76.7

55.3




S225






2bb

CDCl₃, 100 MHz




S227

8.61
8.60
7.56
7.54
7.50
7.48
7.47
7.45
7.42
7.40
7.26
7.22
7.21
7.20
7.20
7.13
7.12
7.11
7.11
6.39
6.38
6.38
5.75




S228

CDCl₃, 100 MHz




2bc



S229

CDCl₃, 365 MHz




2bc


-62.57

S230

0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 ppm



CDCl₃, 100 MHz





2bd


148.1
147.4
147.3
135.3
130.7
130.5
129.3
126.3
126.2
124.0
116.5
111.5


77.3
77.2
77.0
76.7
71.7
59.7
59.4


19.1












-57.64


CDCl₃, 365 MHz





2bf

S237


0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 ppm









CDCl₃, 100 MHz




2bh




S241








CDCl₃, 100 MHz

2bi












CDCl₃, 100 MHz




2bk







S248



S149







S251

8.20
8.15
8.14
8.14
7.37
7.35
7.33
7.26
7.10
7.08
7.04
7.04
7.03
6.99
6.98
6.97
6.96
6.66
6.65
5.95
5.95
5.44
5.42
3.82
2.36
2.33
2.16
2.12
2.04
1.88
1.86
1.77
1.75
1.74
1.72
1.71
1.68
1.67
1.67
1.64
1.63
1.62
1.61
1.61
1.59
1.57
1.54
1.25
1.19
1.17
1.16
1.14
1.13
1.08
1.05
0.92
0.90
0.90
0.88
0.86


CDCl₃, 400 MHz




2bn




S252






S254





CDCl₃, 100 MHz

2bo



S255






S257

9.22
8.99
8.28
8.13
8.12
7.68
7.67
7.66
7.65
7.63
7.61
7.60
7.59
7.58
7.57
7.18
7.17
7.16
7.15


3.78
3.33
2.51
2.50
2.50
2.26
2.25
2.24
2.23
2.23
2.22
2.21
2.21
2.19
1.11
1.10
1.09
1.08
1.08
1.07
1.06
0.99
0.98


(CD₃)₂SO, 400 MHz



2bq


S258





-61.46

(CD₃)₂SO, 365 MHz



2bq

S260

0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 ppm